THE EFFECTS OF OESTRADIOL ADMINISTRATION ON ENERGY METABOLISM DURING PROLONGED EXERCISE IN AMENORRHEIC ATHLETES

SALLY ANN CLARK

Dissertation submitted for the degree of
Master of Science

Department of Physical Education and Recreation
Victoria University of Technology (Footscray)
1996
Clark, Sally Ann

The effects of oestradiol administration on energy metabolism during prolonged
SUMMARY

To delay the onset of fatigue in endurance exercise it is advantageous to prolong muscle glycogen depletion. Oestradiol (the female sex hormone) has been shown to increase muscle glycogen content at rest and increase the availability of fats as a fuel source during exercise therefore delaying the onset of fatigue.

The effects of oestradiol administration on energy metabolism during sub-maximal exercise were examined by administering oestradiol using a transdermal oestradiol therapy system in five amenorrheic athletes. The subjects completed two exercise trials at a workload of 70% VO$_2$ max for a period of two hours. Prior to each exercise trial they underwent three weeks of either an oestradiol or a placebo treatment. A three-week washout period elapsed before the other treatment was administered. In all trials heart rates and perceived exertion were monitored, respiratory gases were collected, blood samples were taken from a vein in the antecubital space and analysed for metabolites and hormones. Pre and post exercise muscle biopsies were taken in two subjects and were analysed for glycogen and lactate.

Results from this study suggest that moderate elevation of serum oestradiol concentrations in amenorrheic athletes has no effect on substrate utilisation during two hours of sub-maximal exercise. There were no significant differences in heart rates, perceived exertion or respiratory exchange ratios, blood and plasma metabolites including glucose, lactate and free fatty acids; or plasma insulin, cortisol and catecholamines. It therefore appears that raising oestradiol concentrations to those achieved in the present study is not advantageous for an amenorrheic athlete during two hours of sub-maximal exercise.
ACKNOWLEDGMENTS

I would like to acknowledge the support of my principal supervisor, Dr. Iva Martin, for her professional guidance and encouragement. I also acknowledge the support of my co-supervisor Dr. Steve Selig for his assistance throughout my candidature.

I would sincerely like to thank Dr. Mark Febbraio for his valued support and for taking the time to teach me many of the analytical skills necessary to complete this thesis.

Many thanks to Associate Professor Mick Carey, Mr Rod Snow and fellow post-graduate students for their ongoing encouragement and for providing a fun and positive environment to work in.

To Dr Glenn Ward for his expert advice and for taking the time to screen all subjects who participated in the present study.

To Dr. Joe Proietto, Sue Fabris, and Michael Clarke for allowing me to use their respective laboratories and for providing me with their technical assistance.

I would like to thank Steve Fraser, Dr. Stuart Malcolm and Dr. Andrew Garnam for all their help during the exercise trials.

To the subjects who participated in the study I thank you for your time and enthusiasm for without you this research could not be possible.

Finally, to my family and friends who have provided me with the encouragement, love and support whilst completing this thesis.
God grant me the serenity to accept the things I cannot change,  
the courage to change the things I can,  
and the wisdom to know the difference.

Reinhold Niebuhr
DECLARATION

This thesis is original and previously unpublished work conducted in the Human Performance Laboratory, Department of Physical Education and Recreation at Victoria University of Technology. With the exception of isotope analyses, which were conducted at St Vincent’s Hospital, Royal Melbourne Hospital, Western General Hospital and Royal Melbourne Institute of Technology, all analyses were conducted in the Department of Chemistry and Biology, Victoria University of Technology. The invasive procedures were, however, conducted by qualified medical personnel and the catecholamine analysis and muscle analysis was done in collaboration with Dr. Mark Febbraio and Mr Rod Snow respectively. This thesis is the result of work performed by the author.

Sally. A. Clark
PREFACE

The results reported in this dissertation which have been presented at the following scientific meeting.

# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>CHAPTER</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><strong>INTRODUCTION</strong></td>
</tr>
<tr>
<td>1.1</td>
<td>Limitations to the Study</td>
</tr>
<tr>
<td>2.</td>
<td><strong>REVIEW OF LITERATURE</strong></td>
</tr>
<tr>
<td>2.1</td>
<td>The Control of the Menstrual Cycle</td>
</tr>
<tr>
<td>2.2</td>
<td>Exercise and the Menstrual Cycle</td>
</tr>
<tr>
<td>2.2.1</td>
<td>Amenorrhea</td>
</tr>
<tr>
<td>2.2.2</td>
<td>Epidemiology and Aetiology of Changes in Menstrual Cycle Status in Athletes</td>
</tr>
<tr>
<td>2.3</td>
<td>Endocrine Mechanisms Responsible for Changes in Menstrual Cycle Function in Athletes</td>
</tr>
<tr>
<td>2.4</td>
<td>Energy Metabolism During Exercise</td>
</tr>
<tr>
<td>2.4.1</td>
<td>Muscle Glycogen Utilisation During Exercise</td>
</tr>
<tr>
<td>2.4.2</td>
<td>Liver Glycogen Utilisation During Exercise</td>
</tr>
<tr>
<td>2.4.3</td>
<td>Fat Utilisation During Exercise</td>
</tr>
<tr>
<td>2.5</td>
<td>Energy Metabolism and Fatigue</td>
</tr>
<tr>
<td>2.6</td>
<td>Sex Steroids and Metabolism</td>
</tr>
<tr>
<td>2.6.1</td>
<td>Oestrogen</td>
</tr>
<tr>
<td>2.6.2</td>
<td>Metabolic Effects of Oestradiol</td>
</tr>
<tr>
<td>2.6.3</td>
<td>Effects of Oestradiol on Muscle Glycogen Levels at Rest</td>
</tr>
<tr>
<td>2.6.4</td>
<td>Effects of Oestradiol on Muscle Glycogen and Lipid Utilisation During Exercise</td>
</tr>
<tr>
<td>2.6.5</td>
<td>The Effect of Sex Steroid Hormones on Other Hormones Controlling Metabolism</td>
</tr>
<tr>
<td>2.6.6</td>
<td>Summary of the Metabolic Effects of Oestradiol</td>
</tr>
<tr>
<td>2.7</td>
<td>Energy Metabolism in the Amenorrheic Female</td>
</tr>
<tr>
<td>3.</td>
<td><strong>METHODOLOGY</strong></td>
</tr>
<tr>
<td>3.1</td>
<td>Subjects</td>
</tr>
<tr>
<td>3.1.1</td>
<td>Recruitment of Subjects</td>
</tr>
<tr>
<td>3.1.2</td>
<td>Selection Criteria</td>
</tr>
<tr>
<td>3.1.3</td>
<td>Subject Instructions</td>
</tr>
<tr>
<td>3.2</td>
<td>Study Design</td>
</tr>
<tr>
<td>3.3</td>
<td>Transdermal Oestradiol Therapy System</td>
</tr>
<tr>
<td>3.4</td>
<td>Measurement of Maximal Aerobic Capacity</td>
</tr>
<tr>
<td>3.4.1</td>
<td>Equipment</td>
</tr>
<tr>
<td>3.4.2</td>
<td>VO₂ Max Protocol</td>
</tr>
<tr>
<td>3.4.3</td>
<td>Prediction of Submaximal Work Intensities</td>
</tr>
<tr>
<td>3.5</td>
<td>Sub-Maximal Exercise Testing</td>
</tr>
<tr>
<td>3.6</td>
<td>Collection of Blood and Muscle Samples</td>
</tr>
<tr>
<td>3.7</td>
<td>Blood Analysis</td>
</tr>
<tr>
<td>CHAPTER</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>3.7.1. Serum Oestradiol and Progesterone</td>
<td>39</td>
</tr>
<tr>
<td>3.7.2. Glucose</td>
<td>40</td>
</tr>
<tr>
<td>3.7.3. Blood and Plasma Lactate</td>
<td>40</td>
</tr>
<tr>
<td>3.7.4. Cortisol and Insulin</td>
<td>40</td>
</tr>
<tr>
<td>3.7.5. Catecholamines and Free Fatty Acids</td>
<td>41</td>
</tr>
<tr>
<td>3.8. Muscle Sample Analysis</td>
<td>41</td>
</tr>
<tr>
<td>3.8.1. Lactate Determination</td>
<td>42</td>
</tr>
<tr>
<td>3.8.2. Glycogen Determination</td>
<td>42</td>
</tr>
<tr>
<td>3.9. Statistical Analyses</td>
<td>43</td>
</tr>
<tr>
<td>4. RESULTS</td>
<td>44</td>
</tr>
<tr>
<td>4.1. Subjects</td>
<td>44</td>
</tr>
<tr>
<td>4.2. Treatment</td>
<td>44</td>
</tr>
<tr>
<td>4.2.1. Oestrogen and Progesterone</td>
<td>44</td>
</tr>
<tr>
<td>4.3. Parameters of Exercise Intensity</td>
<td>47</td>
</tr>
<tr>
<td>4.3.1. Heart Rate</td>
<td>47</td>
</tr>
<tr>
<td>4.3.2. Rating of perceived exertion</td>
<td>47</td>
</tr>
<tr>
<td>4.3.3. Respiratory Exchange Ratio</td>
<td>47</td>
</tr>
<tr>
<td>4.4. Blood and Plasma Metabolites</td>
<td>51</td>
</tr>
<tr>
<td>4.4.1. Plasma Glucose</td>
<td>51</td>
</tr>
<tr>
<td>4.4.2. Blood and Plasma Lactate</td>
<td>51</td>
</tr>
<tr>
<td>4.4.3. Free Fatty Acids</td>
<td>51</td>
</tr>
<tr>
<td>4.5. Hormones</td>
<td>56</td>
</tr>
<tr>
<td>4.5.1. Insulin</td>
<td>56</td>
</tr>
<tr>
<td>4.5.2. Cortisol</td>
<td>56</td>
</tr>
<tr>
<td>4.5.3. Catecholamines</td>
<td>56</td>
</tr>
<tr>
<td>4.6. Muscle Metabolites</td>
<td>61</td>
</tr>
<tr>
<td>4.6.1. Muscle Glycogen</td>
<td>61</td>
</tr>
<tr>
<td>4.6.2. Muscle Lactate</td>
<td>61</td>
</tr>
<tr>
<td>5. DISCUSSION</td>
<td>64</td>
</tr>
<tr>
<td>6. CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE RESEARCH</td>
<td>71</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>72</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>94</td>
</tr>
<tr>
<td>APPENDIX A</td>
<td>94</td>
</tr>
<tr>
<td>APPENDIX B</td>
<td>101</td>
</tr>
<tr>
<td>APPENDIX C</td>
<td>104</td>
</tr>
<tr>
<td>APPENDIX D</td>
<td>108</td>
</tr>
</tbody>
</table>
## LIST OF TABLES

<table>
<thead>
<tr>
<th>TABLE</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Physical characteristics of subjects</td>
<td>45</td>
</tr>
<tr>
<td>4.2</td>
<td>Blood and plasma lactate, plasma glucose, and plasma free fatty acid concentrations at rest and at 120 minutes of exercise</td>
<td>53</td>
</tr>
<tr>
<td>4.3</td>
<td>Plasma insulin, plasma cortisol, plasma catecholamines at rest and at 120 minutes of exercise</td>
<td>58</td>
</tr>
<tr>
<td>4.4</td>
<td>Muscle glycogen concentrations pre and post exercise</td>
<td>62</td>
</tr>
<tr>
<td>4.5</td>
<td>Muscle lactate concentrations pre and post exercise</td>
<td>63</td>
</tr>
</tbody>
</table>
LIST OF FIGURES

FIGURE                                                                                     Page

2.1  The Menstrual Cycle                                                                 5

2.2  The Sequence of Events in the Endocrine Control of the Ovarian Cycle                6

2.3  A Schematic Diagram of the Muscle Cell and its Intracellular and Extracellular Fuel Sources 17

4.1  Oestrogen and Progesterone at rest                                                   46

4.2  Heart rate values during exercise                                                    48

4.3  Ratings of perceived exertion during exercise                                        49

4.4  Respiratory exchange ratio (RER) during exercise                                     50

4.5  Plasma glucose concentrations during exercise                                        52

4.6  Plasma and blood lactate concentrations during exercise                              54

4.7  Plasma free fatty acid concentrations during exercise                                55

4.8  Plasma insulin during exercise                                                       57

4.9  Plasma cortisol during exercise                                                      59

4.10 Plasma adrenaline and noradrenaline during exercise                                 60
CHAPTER ONE

INTRODUCTION

In recent years there has been a marked increase in women participating in physical activity for either recreational or competitive purposes. Both volume and intensity of training have increased in female athletes. This has coincided with an increase in the awareness of exercise-related changes in reproductive function of females, prompting researchers to investigate the effect of exercise on the menstrual cycle and the effect of the menstrual cycle on athletic performance. Menstrual dysfunction in athletes has been associated with changes in body composition (Carlberg et al., 1983; Schwartz et al., 1981), menstrual cycle history (Cavanaugh et al., 1989), training regimes (Bullen et al., 1985), dietary practices (Byran Pedersen et al., 1991; Kaiserauer et al., 1989) and altered hormonal status (Baer, 1993; Boyden et al., 1983). From the literature it would appear that there is no single factor which can account for the reproductive disturbances seen amongst some female athletes.

The effect of the menstrual cycle on athletic performance is of interest to exercise physiologists, coaches, and athletes. Physiological parameters including maximal aerobic capacity tests, ratings of perceived exertion, blood lactate concentrations, respiratory exchange ratios (RER), strength tests and various measures of energy metabolism have been determined during different phases of the menstrual cycle. Studies in women which compared the mid-follicular and mid-luteal phases of the menstrual cycle (low and high oestradiol levels respectively) reported improved endurance exercise performance during the mid-luteal phase (Nicklas et al., 1989). The mechanisms that are thought to be responsible for enhanced performance in the luteal phase of the menstrual cycle include increased muscle glycogen levels prior to exercise (Hackney, 1990) and an increase in the availability and oxidation of free
fatty acids (FFA) in the contracting muscle (Hackney et al., 1990). It is well known that the work capacity of the contracting muscle for endurance exercise is improved with increased glycogen availability (Bergstrom et al., 1967) as well as a high level of FFA oxidation (Costill, 1977). For an endurance athlete it would appear more favourable to compete during the luteal phase of the menstrual cycle when oestradiol levels are high.

Amenorrheic athletes are characterised by having chronically low circulating levels of the ovarian hormones oestrogen (primarily oestradiol) and progesterone (Wilmore et al., 1992). In terms of performance, amenorrheic athletes may be at a disadvantage during prolonged exercise events because of a reduced ability to store muscle glycogen prior to exercise, and a reduced capacity for mobilising fats to use for energy during exercise.

The purpose of the present study, therefore was to determine the effect of oestradiol administration on energy metabolism during prolonged exercise in amenorrheic athletes.

It is also known that amenorrheic athletes are at increased risk of suffering from loss of bone density (Drinkwater et al., 1984), causing a higher incidence of stress fractures (Clark et al., 1988) leading to premature osteoporosis (Parker Jones, 1985) and possibly infertility (Shangold and Levine, 1982). Although these issues are not the subject of this study, the present research may encourage female athletes to monitor any changes which occur to their menstrual status, and seek medical advice which would prove to be beneficial for both their long term health and current exercise performances.
1.1. Limitations to the Study

Recruitment of subjects for the present study proved to be a major problem. The criteria to select subjects were rigid, requiring the subjects to have two or less menstrual cycles per year and not to be taking the oral contraceptive pill. Currently, oral contraceptives are commonly prescribed by medical practitioners for amenorrheic athletes because the oestrogenic component is thought to help protect the athlete from stress fractures and premature osteoporosis. Consequently, only five subjects completed the study and that this small sample size severely compromised the statistical power of the study. In addition, of the five subjects, only two subjects agreed to muscle biopsies and therefore the interpretation of muscle metabolites was limited.
CHAPTER TWO

REVIEW OF LITERATURE

2.1. The Control of the Menstrual Cycle

Although a normal menstrual cycle is typically described as being 28 days in duration, Loucks and Horvath, (1985) defined eumenorrhea as normal menstrual cycles of 23-35 days duration, counting from the first day of menses to the first day of the succeeding cycle.

The menstrual cycle is regulated by hormones of the hypothalamic - pituitary - ovarian (HPO) axis and is divided into two phases (Fig. 2.1). The pre-ovulatory phase, in which the follicles develop is called the follicular phase (FP). The first four to six days of the follicular phase coincide with menstruation. Following ovulation, at about day fourteen the ovary enters the luteal phase (LP) which is characterised by the presence of a functional corpus luteum (Wells, 1991).

The timing of ovulation and the total length of the menstrual cycle shows considerable variation between women, and may vary from cycle to cycle in an individual (Loucks, 1990b). The length of the follicular phase appears to be more variable than the length of the luteal phase, thereby influencing the exact timing of ovulation and the total menstrual cycle duration. To accurately determine the duration of a menstrual cycle requires the analysis of frequent blood, urine or saliva samples for gonadotropin and gonadal steroid hormone concentrations (Keizer and Rogol, 1990). A reasonable assessment of menstrual function, however, may also be obtained from basal body temperature measurements (Prior et al., 1990a).
Fig. 2.1 The Menstrual Cycle. Taken from Villie, C.A., Solomon, E.P., and Davis, P.W. Biology, CBS College Publishing, pg 939, 1985.
Decreased negative feedback inhibition
↑
↓ Oestradiol; ↓ Progesterone
↑
Corpus luteum regresses
↑
OVARIES
↓ FSH; LH
↑
Anterior Pituitary
↑
↓ GnRH
↑
HYPOTHALAMUS
↓
↑ Oestradiol; ↑ Progesterone
↑
Empty follicle becomes a 
corpus luteum

HYPOTHALAMUS
↓
↑ GnRH
↓
Anterior Pituitary
↓
↑ FSH and LH
↓
OVARIES
↓
↓
↓
OVARIES
Increased sensitivity of follicles to FSH
↑
Anterior Pituitary
↑
↓ GnRH
↑
HYPOTHALAMUS
↓
↑ Oestradiol
↓
Anterior pituitary
↓
LH surge
↓
OVARIES
↓
OVULATION

Fig 2.2 The sequence of events in the endocrine control of the ovarian cycle. Taken from Van DeGraff and Fox, pg. 837, 1992.
The changes which take place in the ovary during the menstrual cycle are controlled by complex interactions between the hypothalamus, anterior pituitary gland and the ovaries (Fig 2.2). During the follicular phase of the menstrual cycle, the hypothalamus secretes gonadotropin releasing hormone (GnRH) in a pulsatile fashion. GnRH stimulates the anterior pituitary gland to release luteinising hormone (LH) and follicle stimulating hormone (FSH). FSH and LH are transported via the circulatory system to the ovaries, whereby they stimulate the follicles in the ovary to mature, with only one follicle normally reaching maturity (Wells, 1991). The mature follicle produces oestrogen, primarily beta-oestradiol (Bonen and Keizer, 1984). Prior to ovulation there is a sudden rise in oestradiol, triggering further LH secretion, which superimposes on the cyclic secretions of LH, resulting in an LH surge. The LH surge is responsible for stimulating the release of the ovum (ovulation) and stimulating the portion of follicle that remains in the ovary to develop into the corpus luteum (Villee et al, 1985). The corpus luteum functions as a temporary endocrine gland that secretes both oestrogen and progesterone. The increased levels of oestrogen and progesterone inhibit GnRH pulsations, which decrease FSH and LH secretion so that no further follicles will mature. The corpus luteum begins to degenerate if the ovum is not fertilised and the levels of oestrogen and progesterone fall, stimulating a rise in the gonadotropin hormones (LH and FSH), and resulting in menstruation once again (Villee et al., 1985).

2.2. Exercise and the Menstrual Cycle

2.2.1. Amenorrhea

Amenorrhea is a term used to describe the absence of menstruation. It may be subclassified into primary and secondary amenorrhea. Primary amenorrhea is the delayed onset of menarche beyond the age of sixteen (Loucks and Horvath, 1985).
Secondary amenorrhea is the cessation of menstruation which occurs after menses have initially been established.

There appears to be no clear agreement among researchers upon the precise definition of secondary amenorrhea (Stager, 1984). The criterion used to assess secondary amenorrhea is a menstrual cycle longer than 90 days (Loucks and Horvath, 1985); however, variations do exist, with some researchers preferring to use the criterion of a menstrual cycle longer than 180 days (Prior and Vigna, 1986). These variations in definitions in the literature are a limitation when interpreting results in which amenorrheic women are subjects. For the purpose of this study, the criterion used for amenorrhea was a menstrual cycle longer than 180 days.

Secondary amenorrhea is often termed athletic amenorrhea because of its relatively high prevalence amongst the athletic population (Carlberg et al., 1983). Several reasons for this occurrence have been examined and it appears that athletic amenorrhea is not induced by exercise alone and that other possible mechanisms may exist, which will be discussed in detail subsequently.

2.2.2. Epidemiology and Aetiology of Changes in Menstrual Cycle Status in Athletes

Determination of the incidence of amenorrhea amongst athletic women has been previously assessed through the use of questionnaires. Shangold and Levine, (1982), distributed a questionnaire to all females who had entered the 1979 New York City marathon and they received 394 responses in total (21% of participants). They reported that 24% of all the respondents had oligomenorrhea/amenorrhea during training, and 19% of all the respondents had experienced these problems prior to training. It is recognised that limitations exist when using questionnaires to obtain information in regards to the incidence of amenorrhea amongst the athletic
population. Information collected via questionnaires is often obtained retrospectively and limitations include the individual’s inability to recall information and lack of awareness of changes in menstrual cycle during training (Bonen and Keizer, 1984). Past results obtained from questionnaires however, have established the prevalence of several predisposing factors regarding athletic menstrual cycle irregularity.

The strongest evidence to indicate that amenorrhea in athletes is related to exercise can be found in the work of Bullen et al. (1985). A group of eumenorrheic women who exercised regularly increased their training volume and intensity over a period of two months. Among this group half of the subjects were required to maintain their weight whilst the other half were required to lose weight. The authors reported a significant change in menstrual function in nearly all the subjects. During the two months, fifty three menstrual cycles were analysed and of those, only five were reported to be normal and four of those five were in subjects in the weight maintenance group. In contrast, when increases in exercise intensities were only moderate, changes in menstrual function did not occur (Bonen, 1992). It is also important to note that loss of body weight in conjunction with a large increase in exercise training possibly exacerbates the problem of menstrual cycle alterations.

Changes in body composition is one mechanism which has been held responsible for athletic amenorrhea. Frisch and McArthur, (1974) hypothesised a critical ratio of body fat (17%) is necessary for normal menstrual function to occur, whilst resumption of normal menstrual function following its loss required an increase to 22% body fat. This critical fat ratio hypothesis was developed because it was learnt that adipose tissue was a site of conversion of androgens to oestrogens and for certain oestrogens to other forms of oestrogens. Therefore, if the amount of adipose tissue was decreased, total oestrogen levels would also decrease. The critical fat ratio hypothesis has received criticism from many researchers. It is based on retrospective analysis of observations from growth and development studies (Sinning and Little, 1987) and it
uses the Mellits-Cheek (1970) equation to estimate body fat levels, which has been proven to be inaccurate (Trussell, 1978). Sanborn et al. (1987) compared body fat levels of amenorrheic and eumenorrheic athletes who were matched for somatotype and training load. They reported no difference between the two groups for body fat composition. Bonen and Keizer (1984) postulated that the link between weight loss and secondary amenorrhea which maybe a useful clinical tool but, in actual fact, it is the change in endocrine milieu associated with weight loss rather than fat loss that may stimulate menstrual cycle changes.

The level of maturity of the reproductive system is possibly another factor responsible for maintaining normal menstrual cycle status. A previous pregnancy, early age of menarche and menstrual regularity prior to exercise training are all signs of reproductive maturity and that reproductive maturity is protective against athletic amenorrhea (Loucks and Horvath, 1985). This proposal has been further supported by the relationship between the age of the athlete and the incidence of amenorrhea. Baker et al. (1981b), reported that in a group of runners, 66% of those under the age of 29 (n=12) years were amenorrheic whilst only 9% of women over the age of 30 (n=11) years were amenorrheic. However this study was conducted on a small sample size and may not be representative of the population.

Delayed menarche is considered a sign of reproductive immaturity and has been associated with the incidence of amenorrhea. In a group of 41 cross country runners there was no significant difference between the amenorrheic and eumenorrheic runners for the number of miles run per week, age when training began, skinfold measurements and the number of years they had been training (Wakat et al., 1982). There was however, a difference in the mean age of menarche, with the amenorrheic runners having a higher mean age at menarche. Delayed menarche could possibly represent some sort of endocrine fragility before engaging in heavy training or it could be interpreted as the involvement of an athlete in heavy training prior to puberty.
which may continue to affect the endocrine function (Wakat et al., 1982). Evidence for the latter is provided by the relationship between delayed menarche and premenarchal training (Warren, 1980).

Another mechanism thought responsible for athletic amenorrhea may be hypocaloric diets, which has been termed energy drain. Myerson et al. (1991), observed that female athletes did not have a large enough energy intake to match energy output yet they maintained their weight. It is possible that the females under-reported their food intake or, alternatively, their basal metabolic rate (BMR) was reduced, with associated diminished follicular development. A reduced BMR and amenorrhea in runners may be part of an adaptive syndrome to conserve energy and maintain stable weight in response to the caloric demands of a high level training program that is not compensated by an increase in caloric intake (Myerson et al., 1991). This theory was further supported by Graham et al. (1989) who observed a 17% decrease in oxygen consumption at rest among amenorrheic women compared to eumenorrheic women. Amenorrhea in athletes may be an energy conserving strategy similar to that seen in anorexics (Casper et al., 1991).

There has been growing evidence of changes occurring in the menstrual cycle amongst athletes which can not be defined as amenorrhea but may have implications for the health of the female (Prior et al., 1990b). These exercise-related changes in menstrual function include oligomenorrhea (menstrual cycle lasting between 36-90 days), luteal phase deficiency (luteal phase less than 12 days) and anovulation (absence of egg release) (Prior and Vigna, 1986). Luteal phase deficiency has been observed amongst athletic females who regard themselves as having regular menstrual function (Beintins et al., 1991; Loucks et al., 1989). Loucks et al. (1989) observed that regular cyclic females who participated in frequent bouts of aerobic exercise all had shortened luteal phases by two days, with three subjects having luteal phases less
than ten days. The females who had a shortened luteal phase also had lower progesterone levels during the luteal phase and an extended follicular phase. Loucks, (1990a) in her review claimed that the observed extended follicular phase meant that the overall duration of the menstrual cycle appeared normal and therefore symptomatically the subjects appeared indistinguishable from the sedentary women. The health implications for females suffering shortened luteal phases are unknown. Prior et al. (1990b), observed that females training for a marathon did not increase their prevalence of amenorrhea even though the training did bring about menstrual cycle disturbances including anovulatory cycles and shortened luteal phases. These changes in menstrual function were associated with a decreased production of progesterone and a decrease in spinal bone density. Prior et al. (1990b) concluded that inadequate production of progesterone was associated with accelerated bone loss despite normal production of oestradiol and preservation of what appeared as a normal cycle. It is possible that these changes in the menstrual cycle may be the earliest forms of reproductive dysfunction with severe hypo-oestrogenic amenorrhea at the other end of the spectrum of abnormalities (Warren, 1992).

There is still a lack of evidence for the mechanisms responsible for luteal phase deficiency and whether luteal phase deficiency is an adaptation to physical training in the more robust female or is just an intermediate step which may progress to secondary amenorrhea (Loucks, 1990a). This phenomenon further highlights the need to assess and monitor hormonal patterns in women involved in metabolic studies to ensure their menstrual status can be defined accurately.

2.3. Endocrine Mechanisms Responsible for Changes in Menstrual Cycle Function in Athletes

The normal menstrual cycle is dependent on accurate timing of gonadotropin releasing hormone (GnRH) pulses from the hypothalamus. If the GnRH pulse is
disrupted then there is insufficient stimulus for the pituitary gland to release LH and FSH resulting in either irregular or complete cessation of menstruation (Highet, 1989). Amenorrheic athletes have been observed to have reduced concentrations of LH and FSH (Fisher et al., 1986) which is hypothesised to be a result of a decrease in amplitude in GnRH secretion (Fisher et al., 1986) Evidence to support this is the observation that LH concentrations increased in amenorrheic women after a bolus of GnRH was administered (Loucks et al., 1989). If the GnRH pulse is disrupted and LH is inhibited, there may not be adequate stimulus for ovulation to occur. Without ovulation the corpus luteum cannot develop and so levels of oestrogen and progesterone remain at relatively low levels. Chronically low levels of oestradiol have been observed in amenorrheic athletes compared with eumenorrheic athletes (Baker et al., 1981b; Fisher et al., 1986; Wilmore et al., 1992) which is consistent with the observation of decreased LH release amongst amenorrheic women.

The disruption in GnRH activity is thought to be caused by a hypothalamic neurotransmitter, corticotropin - releasing hormone (CRH). CRH is released from the hypothalamus in response to stress and other stimuli, and has been observed to inhibit the release of GnRH from the hypothalamus in rats (Gambacciani et al., 1986). Increased plasma and urinary cortisol concentrations serve as a marker for increased CRH production. Elevated concentrations of plasma and urinary cortisol amongst amenorrheic athlete have been observed at rest (Ding et al., 1988), and during exercise (Kanaley et al., 1992a) compared with eumenorrheic athletes. The increased values for cortisol which are observed amongst amenorrheic athletes are consistent with greater CRH production.

Several groups have observed that GnRH release may also be inhibited by endorphins (Grossman and Sutton 1985; Laatikainen et al., 1986). Endorphins are produced in the pituitary gland in response to CRH stimulation along with adrenocorticotropic hormone (ACTH) and other active peptides (Findling and Tyrell, 1991). This
inhibition of the hypothalamic secretion of GnRH results in decreased levels of LH (Fisher et al., 1986). Laaitikainen et al. (1986) observed higher beta-endorphin levels at rest in amenorrheic women compared with eumenorrheic women. Contrary to these findings, Dixon et al. (1984) observed no changes to LH and FSH secretion amongst amenorrheic runners when they were given naloxone which is the opioid receptor antagonist. If opioids inhibit gonadotropin secretion in amenorrheic athletes, then an increase in gonadotropins in response to naloxone would have been anticipated (Dixon et al., 1984).

Psychological stress has been observed to elevate dopamine or endogenous opiates and other neurotransmitters which have a role in regulating the reproductive system (Loucks and Horvath, 1985). Athletes engaging in competition regularly may exhibit higher psychological stress and thereby contribute to disrupting the menstrual cycle pattern.

2.4. Energy Metabolism During Exercise

The immediate source of energy for muscular contraction is the high energy phosphate, adenosine 5'- triphosphate (ATP). The breakdown of its high energy bond to form adenosine 5'- diphosphate (ADP) and inorganic phosphate (Pi) releases chemical energy that can be used for work by the contracting muscle. The ATP compound is held in a limited amount in the muscle and needs replenishing if muscle contraction is required for exercise lasting more than 2-3 seconds. During muscle contraction many energy transduction pathways exist and contribute to replenishing ATP stores. Muscle cells can produce ATP by any one or combination of three metabolic pathways. The breakdown of another high energy phosphate, creatine phosphate (CP) and the degradation of glycogen to lactate are two of the metabolic
pathways which lead to resynthesis of ATP. Both pathways function under anaerobic conditions. The third metabolic pathway which requires the presence of oxygen is the aerobic pathway. Aerobic production of ATP occurs inside the mitochondria of the cell and it involves the interaction of two pathways called the tricarboxylic acid cycle and the electron transport chain. The energy produced in these two pathways enables ADP and Pi to reform ATP (Powers and Howley, 1990). The relative contribution of each pathway to energy production depends upon numerous factors including intensity and duration of exercise (Vøllestad and Blom, 1985), individual training state (Hurley et al., 1986), pre-exercise diet (Bergstrom et al., 1967) and hormonal status (Hackney et al., 1990).

The relative amount of carbohydrate to fat utilisation by humans during low and moderate intensity exercise, but not in maximal exercise, can be indirectly determined from ventilatory exchange which calculates the non-nitrogen R-value or respiratory exchange ratio (RER) (Wasserman and Whipp, 1983). RER is the ratio of the volume of expired carbon dioxide to the volume of oxygen taken up by the lungs per unit of time. The oxidation of carbohydrate results in a RER value of 1.0. The oxidation of fats has a RER value of 0.7 because the process requires more oxygen than for carbohydrate (Powers and Howley, 1990). During sub-maximal exercise it is unlikely that the energy provided comes from only one pathway and therefore the exercising RER value would be between 0.7 and 1.

During prolonged, submaximal exercise, the primary sources of energy for the contracting muscle are carbohydrates, fats, and to a lesser extent amino acids (Fig 2.3)
Carbohydrates have a finite storage capacity and a limited regeneration capacity during exercise, therefore the depletion of carbohydrate as a fuel source is associated with fatigue (Coyle et al., 1986). Carbohydrate is stored as glycogen in the body in two forms. Glycogen is stored in skeletal muscles in close proximity to the excitation-contraction mechanism so it can be readily broken down by a process called glycogenolysis. Glycogen is also stored in the liver. Liver glycogen is broken down to glucose (glycogenolysis) and transported to the contracting muscle via the blood. In addition, glucose can be formed in the liver by a process called gluconeogenesis which uses non-carbohydrate metabolic precursors such as lactate and glycerol (Felig & Wahren, 1975).

In contrast with carbohydrate, there is a very large supply of free fatty acids (FFA) that can be mobilised during exercise at low to moderate intensity. Fats provide 37 kJ/gm of energy while carbohydrates only provide 16 kJ/gm. However the maximal energy output from lipid metabolism is lower than either carbohydrate or phosphagen degradation (Hargreaves, 1992).

The mechanisms which control the usage of both these substrates will be outlined in the subsequent sections.

2.4.1. Muscle Glycogen Utilisation During Exercise

Muscle glycogen breakdown is controlled by two enzymes, 1) phosphofructokinase (PFK) and 2) glycogen phosphorylase (Hultman and Harris, 1988). Glycogen phosphorylase exists in two enzymatically interconvertible forms, a and b. The b-isomer is active in the presence of AMP, whereas the a-isomer is active in the absence of AMP (Chasiotis et al., 1982). The increase in glycogenolysis in skeletal
muscle is initiated by the transformation of phosphorylase b to a and this transformation occurs by hormonal mechanisms mediated by cAMP, by increased $[\text{Ca}^{2+}]$ in the sarcoplasm during muscle contraction and by increased levels of inorganic phosphate (Chasiotis et al., 1983).

Hormonal activity, in particular that of adrenaline, is observed to exert a powerful influence on phosphorylase activity (Chasiotis et al., 1983). Adrenaline induces a transformation of phosphorylase b to a in skeletal muscle by a sequence of reactions starting with an increase in activity of adenyl cyclase. The resulting increase in cAMP concentration activates a protein kinase which then catalyses the conversion of phosphorylase b kinase to the active form (Chasiotis et al., 1983). Evidence to support the action of adrenaline on glycogenolysis is the observation that adrenomedullation reduces muscle glycogen breakdown during moderate exercise (Richter et al., 1981c) and when levels of adrenaline are returned to normal by infusion there is an increase in the rate of glycogenolysis (Richter et al., 1981b). In humans, when adrenaline was infused into the single leg during double leg exercise there was an increase in the rate of glycogenolysis (Jansson et al., 1986). In contrast Chesley et al. (1995) observed no increase in the rate of glycogenolysis when adrenaline was infused in humans during aerobic exercise and hypothesised that allosteric regulators may be more important in controlling the rate of muscle glycogen breakdown and not adrenaline (Lavoie et al., 1992). The differences observed in the literature are probably a result of differences in adrenaline doses, the intensity and type of contractile activity performed.
Another hormone which is observed to influence muscle glycogenolysis to a lesser extent is insulin (Costill et al., 1977). When plasma insulin levels are elevated prior to exercise there was a decrease in blood glucose and plasma FFA levels and a greater reliance on muscle glycogen compared when exercising under fasting conditions, i.e. with low insulin levels (Costill et al., 1977).

The level of glycogen present in muscle before exercise has been observed to alter muscle glycogen utilisation during exercise (Hargreaves et al., 1995; Hespel and Richter 1990; Richter and Galbo 1986). Originally it was thought that muscle glycogen availability could not alter muscle glycogen utilisation because the enzyme controlling glycogenolysis has a very low Michaelis constant (Km of 1-2mM glucose units) for its substrate glycogen and therefore the breakdown of muscle glycogen can not be influenced by pre-exercise levels (Newsholme and Leech, 1983). It has been observed that muscle glycogen is not found in a homogenous solution but rather as particles distributed unevenly within a cell and therefore, test tube results may have little meaning and the actual Km of phosphorylase for muscle glycogen in vivo may be higher (Richter et al., 1986). More recently, Hargreaves et al. (1995) observed that during 40 minutes of exercise at 65-70% peak pulmonary O₂ uptake when pre-exercise muscle glycogen availability was increased, there was an increase in muscle glycogenolysis. A possible explanation for this, is that the substrate glycogen binds to phosphorylase which increases its catalytic activity, so that as glycogen stores decrease during exercise so does the glycogenolytic rate (Johnson, 1992).
The availability of other substrates, such as blood-borne glucose and FFA, may influence muscle glycogenolysis during exercise (Coyle et al., 1986; Hespel and Richter 1990; Turcotte et al., 1995). The effect of elevated blood glucose concentration on muscle glycogen utilisation has been observed by either ingesting carbohydrate prior to (Coyle et al., 1985) or during exercise (Coyle et al., 1986). When blood borne glucose levels were elevated by ingesting carbohydrate four hours prior to exercise, the rate of muscle glycogenolysis increased (Coyle et al., 1985) which the authors suggested was a result of greater muscle glycogen availability since insulin levels had returned to resting values prior to the commencement of exercise.

Glucose ingestion 30-60 minutes prior to exercise is observed to increase blood glucose levels and increase muscle glycogenolysis at the onset of exercise (Costill et al., 1977). The rise in blood glucose just prior to exercise results in a rapid increase in insulin. The release of insulin results in metabolic changes which facilitate the rapid uptake of glucose into the muscle and hence lowers levels of blood glucose which has been observed after the first 10-20 minutes of exercise (Costill et al., 1977). Insulin also acts to inhibit FFA availability which therefore would explain the greater reliance on carbohydrate metabolism. The detrimental effect of carbohydrate ingestion prior to exercise has not always been observed, if the increase in insulin is lower, for example after fructose ingestion (Hargreaves et al., 1987).

Ingesting carbohydrates during exercise does not cause a large insulin response and it does not alter the rate of muscle glycogenolysis (Coyle et al., 1986). During prolonged exercise when muscle glycogen levels decrease, there is an increase in ability of muscles to take up blood borne glucose (Hespel and Richter, 1990) and
therefore by ingesting carbohydrates, blood glucose levels are maintained and there is a high rate of carbohydrate oxidation which is observed to increase time to fatigue (Coyle et al., 1986; Coggan and Coyle, 1987).

When levels of FFA are increased by heparin administration there is a decrease in the rate of muscle glycogenolysis (Costill et al., 1977; Hickson et al., 1977) and in contrast, when plasma FFA levels are decreased with nicotinic acid there is an accelerated rate of glycogen degradation during exercise (Bergstrom et al., 1969). It is thought that increasing the rate of FFA oxidation results in a citrate-mediated inhibition of PFK, which causes the accumulation of G-6-P, and therefore inhibits glucose uptake (Rennie and Hollozy, 1977).

More recently, it has been observed that the accumulation of glucose and G-6-P in the muscle was not associated with decreased muscle glucose uptake when arterial levels of FFA were elevated both at rest and during exercise (Hargreaves et al., 1991). Furthermore, the observation that when muscle glycogen content is decreased during exercise, there is an increase in glucose uptake without any effect on plasma FFA oxidation, suggests that regulation within pathways of carbohydrate metabolism takes precedence over regulation between pathways of lipid and carbohydrate metabolism (Turcotte et al., 1995).

2.4.2. Liver Glycogen Utilisation During Exercise

During exercise of long duration (>2 hours), blood borne glucose becomes an important carbohydrate source when muscle glycogen levels are compromised. Although muscle glycogen is the primary storage form of carbohydrate it lacks the enzyme glucose-6-phosphate and therefore cannot release glucose into the blood stream (Felig and Wahren, 1975). The glucose derived from the liver can be released
into the blood stream and therefore during exercise is an important carbohydrate source. During prolonged exercise there is an increase in the uptake of glucose by the contracting muscle and therefore liver glycogen is broken down to glucose and released into the blood stream to maintain blood glucose levels (Wahren et al., 1971). Glucose production in the liver can either be from the direct breakdown of liver glycogen (glycogenolysis) or by the formation of glucose using other metabolic precursors such as alanine, lactate and pyruvate (gluconeogenesis). The contribution of both these pathways is under hormonal control and alters throughout exercise (Ahlborg et al., 1974; Wahren et al., 1971). After four hours of low intensity exercise (30% VO₂ max) gluconeogenesis contributed 45% of the glucose release from the liver compared with 20-25% at rest and after 40 minutes (Ahlborg et al., 1974). This is in contrast with the earlier work of Wahren et al. (1971) who reported that the contribution of glucose production from gluconeogenesis decreased during exercise, however in this study subjects exercised for only 40 minutes which may explain the difference. The liver has a lower storage capacity for glycogen compared with total skeletal muscle and its ability to maintain blood glucose may be limited when muscles are removing glucose from blood at high rates, and blood glucose levels decrease, resulting in hypoglycaemia (Ahlborg et al., 1974).

2.4.3. Fat utilisation During Exercise

During prolonged exercise lipids are an important source of fuel. The onset of exercise results in a fall in plasma FFA concentration. This results mostly from a temporary imbalance between the rate of FFA uptake by muscle and FFA released by adipose tissue. As exercise continues there is a gradual rise in plasma FFA because of an increase in mobilisation from adipose tissue. The major site of triglyceride (TG) storage is the cytoplasm of adipose cells. Small amounts are also present in the cytoplasm of other cells including skeletal muscle and in the blood (Holloszy, 1990). FFA are taken up by the muscle after being esterified in the sarcoplasmic reticulum to
form TG which are then incorporated into lipid droplets in muscle (Linder et al., 1976; Tan et al., 1977). It was observed that between 70-90% of fatty acids entering muscle cells from circulation are esterified to TG (Linder et al. 1976; Tan et al., 1977) with the remaining FFA entering the cell forming a pool of free (non esterified) fatty acids (Terjung et al., 1982; Terjung et al., 1983). A combination of the non esterified fatty acids and the FFA released from TG by lipolysis then undergo beta oxidation in the mitochondria to release energy (Oscai et al., 1990).

Lipolysis of triglycerides stored in adipocytes is stimulated by sympathoadrenal factors and low plasma insulin values (Bulow and Madsen, 1986). The decline of plasma insulin during exercise is accompanied by increases in lipolysis, partly as a result of reduced antagonism of the stimulatory actions of catecholamines and glucagon (Martin and Wahren, 1993). Catecholamines stimulate adenylate cyclase and cAMP which activates the hormone sensitive TG lipase, and therefore the subsequent hydrolysis in the adipose tissue (Gorski, 1990). This enables fatty acids to be mobilised in excess of FFA utilisation by muscle therefore resulting in an increase in arterial FFA content. A subsequent increase of FFA concentration in the circulating blood causes an increase in muscle uptake and utilisation of fatty acids (Bulow and Madsen, 1986).

It has become evident that another source of lipids besides blood-borne FFA exists with the observation that trained endurance athletes oxidised more fats during exercise compared with the untrained (Hurley et al., 1986). It appears the rate at which muscle oxidises FFA is determined not only by plasma FFA concentration but by the concentration of FFA in the cytoplasm to which the mitochondria are exposed (Hurley et al., 1986).

The regulation of the breakdown of muscle triglyceride is not understood at rest or during exercise (Gorski, 1990). Mobilisation, however, appears to be under both
adrenergic and noradrenergic control. An increase in lactic acid inhibits muscle TG lipolysis, whilst the reduction of carbohydrate during exercise appears to enhance the mobilisation of muscle triglycerides (Gorski, 1990).

2.5. Energy Metabolism and Fatigue

During prolonged exercise at moderate to high intensity, carbohydrates are a major source of fuel for the contracting muscle. At the onset of exercise, muscle glycogen is the primary source of carbohydrates used for energy (Felig and Wahren, 1975). At workloads between 65-85% VO₂ max, muscle fatigue is highly correlated with muscle glycogen depletion (Bergstrom et al., 1967).

The development of the muscle biopsy technique enabled the confirmation of the relationship between endogenous muscle glycogen and the ability to sustain exercise. The relationship between muscle glycogen and exercise performance has been further illustrated by several techniques which manipulate either the pre-exercise levels of glycogen or alter the reliance on muscle glycogen as a fuel source by altering the exogenous fuel sources such as free fatty acids and glucose (Coyle et al., 1986; Coggan and Coyle, 1987; Costill, 1977).

Bergstrom et al. (1967) reported a significant correlation between initial glycogen levels and exercise performance. In their study subjects exercised to exhaustion and then they consume either a i) mixed, ii) high fat and protein, or iii) high carbohydrate diet for three days. After the three days the subjects exercised again until exhaustion. The high carbohydrate diet elevated resting levels of glycogen compared with the other two diet regimes and increased exercise time to exhaustion.

When blood glucose levels are maintained by ingestion of carbohydrates during exercise there is a distinct shift to energy derived from blood glucose and therefore
delaying the use of muscle glycogen (Coyle, 1991). The lowering of blood glucose during the later stages of prolonged exercise results in the inability of skeletal muscle to take up sufficient glucose to offset the reduced muscle glycogen availability (Coyle, 1991).

Why glycogen depletion coincides with fatigue when large amounts of fatty acids are still available is unclear (Felig and Wahren, 1975). One proposed mechanism is that glycogen provides glucose moieties that are subsequently metabolised to pyruvate. The pyruvate is carboxylated to oxaloacetate which is used to maintain the citric acid cycle function. When glycogen is depleted, citric acid cycle intermediates such as oxaloacetate decrease, the processing of acetyl groups from beta oxidation of fatty acids is impaired and therefore there is insufficient formation of ATP. This mechanism has been supported by the findings of reduced levels of citric acid cycle intermediates during exercise to fatigue (Sahlin et al., 1990).

In addition to low glycogen levels, other mechanisms have been proposed to contribute to fatigue during exercise. The inability to sustain force output during prolonged sub-maximal exercise could be caused by any one of a number of processes either involved in the activation of the muscle or in the translation of the neural signal into force generation within the muscle (Green, 1991), and further research is required to examine and understand these mechanisms.

2.6. Sex Steroids and Metabolism

2.6.1. Oestrogen

Oestrogens, particularly oestradiol, play an important role in reproductive function. Differential sex characteristics among males and females, and maintenance of
reproductive organs are the result of differing ratios of oestrogens to androgens. The major oestrogen produced in females is oestradiol (E2) whilst oestrone (E1) and oestriol (E3) have a less potent effect (Bunt, 1990). Oestradiol is responsible for the changes in secondary sexual characteristics that take place at puberty, control of the menstrual cycle and also contributes to the function of other metabolic processes including the modulation of bone reabsorption (Balfour and Heel, 1990). The production rates and blood concentrations vary at different phases of the menstrual cycle (Shangold, 1984). During the early follicular phase of the menstrual cycle, concentrations of oestrogen are low, rising to their highest just prior to ovulation. After ovulation both the hormones oestradiol and progesterone are produced by the corpus luteum and decline at the end of the luteal phase if fertilisation has not occurred (Villee et al., 1985). Oestrogen is secreted by the ovary and a small amount is produced from the adrenals (Bunt, 1990). Muscle and fat tissue are able to convert androgens to oestrogens, specifically oestrone (Keizer et al., 1982). However, oestrone produced by this pathway is negligible compared with that produced by the ovaries. Most of the oestrogens circulating in the blood are bound to proteins including sex steroid binding protein (SBP) and albumin. Only a small fraction (1-3%) is present in the unbound state, and it is this fraction which is thought to be biologically active (Keizer et al., 1982). Basal body temperatures vary between the luteal and follicular phases of the menstrual cycle (Stephenson et al., 1982b) and this may influence the ratio between bound and unbound steroid concentrations (Bonen and Keizer, 1984). Higher body temperature which have been reported during the luteal phase of the menstrual cycle may cause steroids to dissociate from their protein
causing an increase in free fraction and presumably biological activity (Bonen and Keizer, 1984).

Progesterone, another ovarian steroid has been observed to have an antioestrogenic effect (Carrington and Bailey, 1985). It is therefore difficult to compare the menstrual cycles between females because of the variation in progesterone levels altering the ratio of oestrogen to progesterone. For example when oestrogen levels are high during the luteal phase of the menstrual cycle so to are levels of progesterone which may counteract the oestradiol actions (Bunt, 1990).

2.6.2. Metabolic Effects of Oestradiol

The metabolic effects of oestradiol appear to be direct on tissues such as liver, muscle and adipose (Carrington and Bailey, 1985; Hackney, 1990; Matute and Kalkhoff, 1973), or indirect by influencing other metabolic hormones such as insulin and glucagon (Mandour et al., 1977; Matute and Kalkhoff, 1973).

The metabolic effects of oestradiol have been well documented through the use of rodent studies (Kendrick and Ellis, 1991; Kendrick et al 1987; Matute and Kalkhoff, 1973; Rooney et al., 1993). In humans, information in regards to the metabolic actions of oestradiol have been observed in studies which compare phases of the menstrual cycle in eumenorrheic women (Hackney et al., 1990; Jurowski et al., 1981; Lavoie et al., 1987 Nicklas et al., 1989) and by observing the effects of synthetic oestradiol in the form of the contraceptive pill (Bemben et al., 1992).

The extent to which oestradiol exerts metabolic effects at rest, and during exercise are outlined in section 2.6.3. and 2.6.4.
2.6.3. Effects of Oestradiol on Muscle Glycogen levels at Rest

Administration of oestradiol in rodents increases glycogen content in the liver (Matute and Kalkhoff, 1973) and skeletal muscle tissue (Carrington and Bailey, 1985) which is thought to occur because of an oestradiol-mediated suppression of hepatic gluconeogenesis whilst promoting liver glycogen deposition (Matute and Kalkhoff, 1973). When oestradiol is administered in combination with progesterone there is also an increase in muscle glycogen (Carrington and Bailey, 1985) and liver glycogen content (Matute and Kalkhoff, 1973) however not to the same magnitude as when oestradiol only is administered (Carrington and Bailey, 1985).

The metabolic effects of oestradiol on resting muscle glycogen content in females was observed by comparing the mid-follicular with the mid-luteal phase of the menstrual cycle when concentrations of oestradiol are low and high respectively. When concentrations of oestradiol were elevated there was an observed increase in resting muscle glycogen content after 36 hours of no strenuous exercise and consumption of a mixed diet (Hackney, 1990). In addition, muscle glycogen repletion during three days recovery after exhaustive exercise was observed to be greater during the mid-luteal phase of the menstrual cycle when oestradiol levels are elevated (Nicklas et al., 1989).

2.6.4 Effects of Oestradiol on Muscle Glycogen and Lipid Utilisation During Exercise

The well documented metabolic effect of oestradiol on muscle glycogen at rest led researchers to investigate metabolic actions of oestradiol during exercise. During prolonged sub-maximal exercise, the administration of oestradiol decreased liver and skeletal muscle glycogenolysis in female ovariectomized (Kendrick et al, 1987) and male (Kendrick and Ellis, 1991) rats by altering the temporal pattern of glycogen depletion (Rooney et al., 1993) despite there being no difference in pre-exercise muscle and myocardial glycogen content (Kendrick and Ellis, 1991). This altered pattern of glycogen depletion is thought to be mediated by a shift towards lipid
metabolism which is supported by increased circulatory levels of FFA (Kendrick and Ellis, 1991) and muscle TG levels (Rooney et al., 1993) at rest, and during prolonged exercise.

Hackney et al. (1990), examined substrate utilisation in women during sixty minutes of exercise at 70% maximal VO$_2$ and under three different hormone conditions. Subjects were tested in the mid-follicular phase (low oestradiol and progesterone), at ovulation (high oestradiol and low progesterone) and during the mid-luteal phase (high oestradiol and progesterone). The authors reported lower (P<0.05) RER values and greater fat oxidation (g/min) during ovulation compared with mid-follicular but not mid-luteal phase, suggesting an increased utilisation of lipids when oestradiol levels are elevated. It is however, not possible to determine whether the rate of muscle glycogenolysis was different between the phases of the menstrual cycle because muscle samples were not obtained.

Lavoie et al. (1987) measured the substrates glucose, lactate, FFA, and glycerol during ninety minutes of exercise at 60% max VO$_2$ after a carbohydrate deplete diet during the mid-luteal and the mid-follicular phase of the menstrual cycle. The prolonged exercise bout and the carbohydrate deplete diet were designed to reduce liver glycogen content and increase the metabolic demands of the muscle and consequently increase the potential metabolic influences of the sex hormones. When oestradiol levels were higher, plasma glucose levels were lower after 70 and 90 minutes of exercise and when oestradiol and progesterone levels were decreased (during the mid-follicular phase) plasma lactate levels were increased. Lavoie et al. (1987) suggested that lowered liver glycogen stores due to a low carbohydrate diet may have increased gluconeogenesis in the liver and that the ovarian hormones may inhibit that action hence the lowered blood glucose levels during the exercise.
There is conflicting evidence in relation to the menstrual cycle effect on plasma lactate levels. Lactate levels have been reported to be elevated in the follicular phase of the menstrual cycle during exercise (Bullen et al., 1984; Jurowski, 1981), and in recovery (McCracken et al., 1994) whilst others have reported no difference (DeSouza et al., 1990; Lamont, 1986).

The metabolic actions of oestradiol and progesterone during exercise have been further examined by investigating the effect of the oral contraceptive pill. There have been many advances in oral contraceptive formulations which is beyond the scope of this thesis to define, however for further information the reader is referred to the review by Bemben, (1993).

During mild (40% VO$_2$) and intense (85% VO$_2$) exercise plasma FFA and blood glucose concentrations were higher amongst subjects on oral contraceptives (OC) compared with the controls. However, it is important to note that in the same study there was no difference in RER values between the two groups and the subjects only exercised for thirty minutes which may not be long enough to demonstrate an greater fat utilisation. Bemben et al., (1992) completed a similar study, however subjects exercised for 90 minutes at 50% VO$_2$. Calculations from RER values indicated that OC users utilised significantly lower levels of carbohydrate during exercise compared with controls, despite no difference in FFA utilisation. Whether this discrepancy can be accounted for by differences in protein utilisation could not be determined in this study.

During exercise the OC users had a higher growth hormone (GH) response and utilised significantly less carbohydrate compared with controls (Bemben et al. 1992). It has been postulated that OC users demonstrate a greater ability to spare
carbohydrate than controls because of a contra-insulin effect of GH. The carbohydrate sparing mechanism may be a compensatory mechanism for decreased hepatic glucose output as observed in animals (Matute and Kalkhoff, 1973). These studies further highlight that the female sex steroid hormones do exert a strong influence on endocrine and metabolic actions during exercise.

2.6.5. The Effect of Sex Steroid Hormones on Other Hormones Controlling Metabolism

Oestradiol also exerts its influence by altering the levels of other hormones (Matute and Kalkhoff, 1973; Mandour et al., 1977; Sutton et al., 1980). Oestradiol administration has been observed to increase plasma insulin concentration (Matute and Kalkhoff, 1973) and decrease glucagon in relation to insulin (Mandour et al., 1977) and therefore increase the rate of enzymes involved in hepatic lipogenesis (Mandour et al., 1977). Progesterone does not appear to alter the ratio of insulin to glucagon and consequently was observed to have no effect on fasting plasma glucose and triglyceride content (Mandour et al., 1977).

Sutton et al. (1980) studied the effect of exercise during the luteal and follicular phase of the menstrual cycle on plasma catecholamine response in eumenorrheic women. Plasma concentrations of adrenaline were increased during exercise in the follicular phase compared with the luteal phase of the menstrual cycle when levels of oestradiol were low. Plasma concentrations of glucose and lactate were observed to be higher in the follicular phase which is consistent with an increased stimulation of muscle and liver glycogenolysis (Sutton et al., 1980). It is possible that oestradiol may exert a metabolic effect during exercise by altering the catecholamine response.
2.6.6. Summary of the Metabolic Effects of Oestradiol

The metabolic effects of oestradiol have been observed in humans by comparing the different phases of the menstrual cycle and by observing the effects of synthetic oestradiol. Oestradiol has been observed to exert a direct metabolic effect by increasing resting glycogen content in liver of rodents (Matute and Kalkhoff, 1973) and skeletal muscle of humans (Hackney, 1990). It also promotes a shift towards lipid metabolism during exercise (Kendrick and Ellis, 1991). Finally oestradiol has been observed to exert an indirect metabolic effect by altering the activities of other glucoregulatory hormones such as catecholamines, insulin and glucagon.

2.7. Energy Metabolism in the Amenorrheic Female

Substrate metabolism has been investigated in the amenorrheic athlete (De Souza et al., 1990; Kanaley et al., 1992b). In both studies amenorrheic women were compared with eumenorrheic women for hormone and substrate responses during maximal and submaximal exercise. De Souza et al. (1990) reported no difference between amenorrheic and eumenorrheic women for heart rate, plasma lactate, and RER values. The authors concluded that amenorrheic athletes therefore suffer no performance disadvantages as a result of their menstrual status. Similarly, Kanaley et al. (1992b) compared amenorrheic and eumenorrheic women during 90 minutes of exercise at 60% max VO\textsubscript{2}. They reported that there was no difference amongst the two groups for substrate utilisation which was determined by indirect calorimetry respiratory exchange ratios (RER). The authors suggested that because the amenorrheic subjects were well trained they may have adapted their use of fuel for energy by utilising more fat. This adaptive mechanism may have masked any effect of the sex hormones. It is worth considering the problems associated with comparing the
two separate groups. When one compares the two phases of the menstrual cycle, the subject acts as her own control. In a comparison of amenorrheic women to eumenorrheic women, there is no control. Consequently further studies are needed to better define the role of changes in sex steroid hormone levels in energy substrate utilisation amongst amenorrheic women.
3.1. Subjects

3.1.1. Recruitment of Subjects

Subjects were recruited in the present study by a variety of methods. Initially letters were sent to every Victorian athletics, cycling and triathlon club and followed up by a telephone call. A letter was written to the Victorian Institute of Sport requesting assistance and was followed up with a meeting with the executive director. Letters were written to physicians at Prahran, Olympic Park and McKinnon Sports Medicine Clinics requesting the physicians to refer any interested patients that met the criteria. Notices were placed at Victoria University of Technology, Royal Melbourne Institute of Technology, The University of Melbourne and Monash University. In addition notices were placed at leisure facilities such as The State Swimming Centre and Kew Recreation Centre. The study gained media attention and requests for participation were printed in The Age newspaper and announced on radio. Despite the intensive recruitment process only five volunteers finally were recruited to participate in this study.

3.1.2. Selection Criteria

Amenorrhea was defined as a menstrual cycle greater than 180 days without any menstrual bleeding in the three months prior to testing. None of the subjects was taking an oral contraceptive pill or had done so in the eighteen month period prior to testing. All subjects were required to answer a questionnaire regarding menstrual cycle and exercise training histories (Appendix A). In addition, all subjects were
screened by an endocrinologist to ensure that there were no contraindications for oestradiol treatment. A single blood sample was taken for determination of serum oestradiol concentration for each subject (Appendix D).

The author attempted to recruit subjects with a Max VO$_2$ greater than 45 ml.kg.min$^{-1}$, however, as a result of recruitment problems subjects with a lower VO$_2$ max were recruited if they were participating in regular endurance exercise.

3.1.3. Subject Instructions

Prior to participation in the study each subject was informed of the possible risks associated with the study and was required to sign an informed consent form (Appendix A). Subjects were free to withdraw from the study at anytime. The study was approved by the Victoria University Human Research Ethics Committee.

Subjects were required to report to the laboratory on three separate occasions. On their first visit, subjects performed a maximal aerobic capacity test on the cycle ergometer, measurements of skinfolds (Appendix B), and measurements of height and weight. The next two visits to the laboratory, subjects were to report in before 8am after an overnight fast and having refrained from tobacco, alcohol, caffeine and strenuous physical activity for the 24 hours prior to the exercise trial. Subjects were instructed to record their diet and all physical activity for the period of 72 hours prior to each exercise trial. The record was copied and handed back to the subjects to be followed again before subsequent trials in an effort to minimise substrate variation. During the nine weeks of the study the subjects were also instructed to maintain their level of training in terms of volume and intensity. Following the exercise trials subjects who had undergone muscle biopsies were instructed to refrain from cycling or running for 24 hours and swimming for 72 hours to avoid any complications.
3.2. Study Design

The study was of a double blind cross over design with neither the subjects nor the experimenter knowing the treatment order.

The study protocol consisted of two exercise trials. Preceding each trial, the subjects underwent a treatment for a period of three weeks. The first trial occurred at the end of the three week treatment period. Each subject then went through a washout period for another three weeks before starting the second treatment. At the completion of the second three week treatment period the subject completed the second exercise trial.

The subjects were randomly allocated to treatments, with some subjects receiving the oestradiol treatment first and others receiving the placebo first. The administration of the oestradiol to the subject involved using a transdermal oestradiol system. A full description of this therapy is outlined in section 3.3.

3.3. Transdermal Oestradiol Therapy System

The transdermal oestradiol delivery system (Trademark Estraderm Ciba Geigy Pharmaceutical Company) is a rate controlled system that delivers oestradiol through the skin and is commonly prescribed for the treatment of menopausal symptoms. The system consists of a thin adhesive patch containing a drug reservoir, where oestradiol is held in ethanolic solution. The two layers surrounding the drug reservoir consist of 1) an adhesive backing layer
2) a rate controlling microporous membrane.

To apply the patch to the skin, the subjects removed the backing and pressed the patch into place. The patch was worn on either the abdomen or buttocks. The oestradiol was delivered at a constant rate to the skin surface to be absorbed into the systemic system for circulation. Currently three sizes of delivery system are available with nominal delivery rates of 0.025, 0.05, and 0.1 mg.day\(^{-1}\). The recommended initial dose for the treatment of menopausal symptoms is 0.05mg.day\(^{-1}\) for a period of four
weeks (3 weeks on, one week off) with the patches being changed twice a week (Balfour and Heel, 1990). With this information and after consultation with the endocrinologist, G.M. Ward (Personal Communication) the dose of 0.05mg.day\(^{-1}\) was chosen for the subjects in the present study. The subjects changed their patch every four days with the last patch applied the day prior to the exercise trial. The placebo patch used in the study consisted of all the components of the oestradiol patch with the exception of the active ingredient of oestradiol. Subjects were advised to rotate the site of application of the patch to prevent skin irritation.

3.4. Measurement of Maximal Aerobic Capacity

3.4.1. Equipment

Maximal oxygen uptake (VO\(_2\) max) tests were conducted on a friction-braked bicycle ergometer (Monark Ergomedic 814E) using open circuit spirometry. Expired air was directed by a Hans - Rudolf valve and plastic tubing into a mixing chamber and through a ventilometer (Pneumoscan 830). Aliquots of the expired air were pumped from the mixing chamber through O\(_2\) (Applied electrochemistry S - 3A) and CO\(_2\) (Applied electrochemistry CD - 3A) analysers. VO\(_2\) and RER were calculated using standard equations (Consolazio et al., 1963). During all maximal aerobic capacity tests the subject's nose was occluded by a nose clip.

3.4.2. VO\(_2\) Max Protocol

All VO\(_2\) max tests consisted of an incremental test to volitional fatigue. The criteria used to determine maximal aerobic capacity were 1) a plateau or decrease in VO\(_2\) with an increase in work 2) RER > 1.1 or 3) volitional fatigue.
Subjects remained stationary for three minutes so resting data could be collected. Subjects then began cycling at 100 watts with the resistance increasing by 50 watts every three minutes for twelve minutes and then by 25 watts for every minute thereafter until volitional fatigue.

### 3.4.3. Prediction of Submaximal Work Intensities

The relationship between steady state submaximal $\text{VO}_2$ ($\text{ml.kg.min}^{-1}$) values and corresponding workloads was determined using a linear regression equation. From these equations a workload which would elicit 70% of $\text{VO}_2$ max was calculated. The criterion for a correlation was set at $R > 0.98$ (workload vs $\text{VO}_2$).

### 3.5. Sub-Maximal Exercise Testing

At each thirty minute interval during the two hour exercise trial, subjects provided a rating of perceived exertion (RPE) by using the 20 point Borg Scale (Borg, 1982) and expired air was collected over a period of 90 seconds. Expired air samples were collected in Douglas bags. The fraction of $\text{CO}_2$ and $\text{O}_2$ were subsequently measured on the gas analysers previously mentioned. The volume of expired air was measured using a gas meter (Parkinson Cowan) and calibrated against a Tissot Spirometer. These analyses were used to confirm that the subjects were actually working at 70% Max $\text{VO}_2$.

Heart rate was also measured at thirty minute intervals using a three lead electrocardiograph (ECG). Subjects were allowed *ad libitum* consumption of water during their first trial. The volume consumed was recorded and subject consumed the same quantity during the second trial.
3.6. Collection of Blood and Muscle Samples

Blood samples were collected from an indwelling teflon catheter (Jelco 20G) which was inserted into a vein in the antecubital space. Following the insertion of the catheter the subject remained lying supine for at least fifteen minutes before two resting samples were taken five minutes apart. The catheter was kept patent by filling it with a small amount of 0.9% NaCl after each blood sample collection. Blood was collected every thirty minutes during the two hour exercise trial. A total of 140 ml of blood was collected during the two hour period.

In two of the subjects muscle samples were obtained from the vastus lateralis muscle using 5mm (Stille) needles (Bergstrom, 1962) modified to include suction (Evans et al., 1982). An incision was made approximately 10 cm proximal to the lateral epicondyle of the femur after a local anaesthetic (1% Xylocaine) was injected subcutaneously over the incision site. Two biopsies were taken from the one incision and an effort was made to angle the needle away from the previous biopsy site in order to avoid the influence of acute trauma on the successive biopsy specimen (Costill et al., 1977). Samples were quickly frozen and stored in liquid nitrogen (LN2) until analysis. The estimated time from the cessation of exercise to freezing in post exercise samples was 20 seconds.

3.7. Blood Analysis

3.7.1. Serum Oestradiol and Progesterone

After sampling 10 ml of blood was placed in a sterile tube and was allowed to clot at room temperature. At the completion of the trial the blood was centrifuged at 1200 rpm and the serum was removed and stored at -80°C. Oestradiol and Progesterone were measured using a standard technique (Ciba Corning ACS Oestradiol competitive chemiluminescent immunoassay).
The assays were performed by technical staff at St Vincent’s and Western General Hospital.

3.7.2. Glucose

After sampling, approximately 2 ml of blood were placed in a fluoride heparin tube, mixed, placed on ice and centrifuged at 4°C for ten minutes at 4000 rpm. The plasma was transferred to another tube and stored at -80°C until analysis using an automated glucose analyser employing the glucose oxidase method (YSI model 23AM).

3.7.3. Blood and Plasma Lactate

Blood was placed in a lithium heparin (anticoagulant) tube and mixed. A 500μl aliquot of blood was transferred to a tube containing 1 ml of 3M perchloric acid (PCA), mixed, place on ice and spun in a centrifuge at 4000 rpm for 10 minutes. The supernatant was transferred to another tube and was stored at -80°C until analysis. Anticoagulated blood was centrifuged and a 500 μl aliquot of the plasma was transferred into a tube containing 1 ml of 3M PCA and treated as for blood lactate. Plasma and blood lactate analysis was performed on a spectrophotometer (Shimadzu UV - 120) using an enzymatic technique (Appendix C) (Lowry & Passonneau, 1972).

3.7.4. Cortisol and Insulin

Plasma was separated from anticoagulated blood by centrifugation and stored at -80°C until analysis.

Plasma cortisol was determined by Radioimmunoassay as prescribed in the ICN Biomedical Immuchemistry Cortisol Coated tube $^{125}$I Radioimmunoassay Kit (Cat No. 60380-03).

Plasma insulin concentration was determined by radioimmunoassay as prescribed in the Incstar Insulin $^{125}$I Radioimmunoassay Kit (Cat. No. 06130). Each sample was counted for one minute on a gamma counter (LKB Wallac 1277 Gamma Master).
3.7.5. Catecholamines and Free Fatty Acids

A preservative was prepared by dissolving 2.25g of ethleneglycol - bis-(betaaminoethylether)N, N'-tetraacetic acid (EGTA) and 1.5g reduced glutathione (GSH) in 25ml of normal saline (0.9% sodium chloride w/v) and adjusted to 6-7.4 pH with 5-10M NaOH. Aliquots of this preservative (20μl per 1ml of whole blood) were placed in tubes and stored on ice. The appropriate volume of blood was added to the tubes, mixed gently, and centrifuged at 4°C for fifteen minutes at 1500rpm (900g). The supernatant was transferred to another tube and stored at -80°C until analysis. Samples were analysed for plasma catecholamines by a modification of the single isotope [3H] radioenzymatic assay of Passon & Peuler, (1973) as described in the Amersham Catecholamine research assay system (code TRK 995). Each sample was counted for ten minutes on a beta counter (Packard Tri-Carb 4000).

Free fatty acids (FFA) were determined by a modification of the enzymatic colorimetric method for determination of non-esterified acids (NEFAC) of Miles et al. (1983) as described in the Wako NEFAC kit (code no. 990-75401).

3.8. Muscle Sample Analysis

The portion of muscle sample collected was freeze dried for 48 hours, weighed, powdered and portioned out for glycogen and lactate analysis. The first portion (approximately 2 mg) was used for the analysis of lactate using standard enzymatic techniques with fluorometric detection. The second portion (approximately 1mg) was used for the measurement of glycogen.
3.8.1. Lactate Determination

A portion of powdered muscle was extracted according to the procedure of Harris et al. (1974). The tubes containing the samples were placed on ice, and 250μl of ice cold 0.5M PCA/1mM ethlenediaminetetra-acetic acid (EDTA). The tubes were periodically mixed on a vortex for a period of 10 minutes. The samples were then spun in a centrifuge (Heraeus Sepatech Biofuge 28RS) at 28,000 RPM (51,000 g) at 0°C for two minutes. After centrifugation, 200μl of supernatant was transferred to a pre-cooled, Eppendorf tube. The extract was neutralised with 50μl of 2.1M ice-cold potassium bicarbonate (KHCO₃), mixed and kept on ice for five minutes to ensure complete precipitation of perchlorate ions. The samples were then mixed again and spun in a centrifuge as described before. The supernatant was transferred to another eppendorf tube and was analysed immediately.

Lactate was analysed using standard enzymatic techniques with fluorometric detection (Turner Model 112) according to the procedure of Lowry and Passonneau (1972). (Appendix C).

3.8.2. Glycogen Determination

The portions of powdered muscle were hydrolysed in 250 μl of 2M hydrochloric acid (HCl) at 100°C for two hours with periodical agitation. The samples were subsequently neutralised by addition of 750μl 0.67M sodium hydroxide (NaOH) before analysis. The extract was then analysed for glucose according to the procedure of Passonneau and Lavderdale (1974), (Appendix C).
3.9. Statistical Analyses

Two way (time by treatment) analysis of variance with repeated measures (ANOVA) was used to compare data between trials. When analysis revealed a significant interaction, simple main effects and Newman Keuls post hoc analyses were used to locate differences. A BMPD computer software program was used to compute these statistics. Student t-tests was also used for paired comparisons. The level of probability to reject the null hypothesis was set at $P<0.05$. All data are reported as means ± the standard error of the mean (SE).
CHAPTER FOUR

RESULTS

4.1. Subjects

The physical characteristics of the subjects are presented in Table 4.1 and include the menstrual cycle characteristics. The subjects consisted of three triathletes, one rower and one ballet dancer. Two of the five subjects were involved in physical training prior to menarche, whilst the other three subjects began physical training after menarche. The five subjects reported menstrual irregularities after either changing their physical training regime, or substantially increasing the number of hours spent training. The subjects that had previously been on the contraceptive pill had stopped taking the oral contraceptive pill for at least two years prior to the commencement of the study. At the time of the subjects’ involvement in the study, the subjects spent a mean time of 16.8 ± 3.0 hours in training per week.

4.2. Treatment

4.2.1. Oestrogen and Progesterone

Resting concentrations of oestradiol and progesterone are presented in Fig. 4.1. Resting mean concentrations of oestradiol were higher (P<0.05) for all subjects after the three week period wearing the treatment patch compared with the control patch (114 ± 17 vs 81 ± 6.7 pmol.l⁻¹). Resting concentrations of progesterone were not statistically different between the TRE (1.46 ± 0.89) and CON (1.04 ± 0.33 pmol.l⁻¹). When oestradiol and progesterone are expressed as a ratio (E₂ : Pg) there was no difference (P=0.06) between the TRE and CON treatments.
<table>
<thead>
<tr>
<th>Physical Characteristic</th>
<th>Mean ± S.D.</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>24.6 ± 3.9</td>
<td>20 - 30</td>
</tr>
<tr>
<td>Age at menarche (yrs)</td>
<td>13.6 ± 1.1</td>
<td>13 - 15</td>
</tr>
<tr>
<td>No. of menstrual cycles per year</td>
<td>1.8 ± 1.6</td>
<td>0 - 3</td>
</tr>
<tr>
<td>Training hours per week (hrs)</td>
<td>16.8 ± 6.7</td>
<td>15 - 25</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>174.6 ± 6.3</td>
<td>174 - 185</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>61.42 ± 8.0</td>
<td>49 - 71</td>
</tr>
<tr>
<td>Skinfolds* (mm)</td>
<td>70.5 ± 7.2</td>
<td>69.6 - 77.9</td>
</tr>
<tr>
<td>BMI (kg.m(^{-1}))</td>
<td>20.2 ± 1.1</td>
<td>19-21.5</td>
</tr>
<tr>
<td>VO(_2) max (ml.kg(^{-1}).min(^{-1}))</td>
<td>48.43 ± 1.6</td>
<td>35.87 - 56.12</td>
</tr>
<tr>
<td>VO(_2) max (l.min(^{-1}))</td>
<td>3.01 ± 0.6</td>
<td>1.75 - 3.37</td>
</tr>
</tbody>
</table>

**Table 4.1.** Physical characteristics, menstrual history and training volume of the study subjects (n=5).

* Sum of seven sites (See Appendix B)
Fig. 4.1. Serum oestradiol and progesterone concentrations at rest under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).

* indicates difference at (P<0.05).
4.3. Parameters of Exercise Intensity

4.3.1. Heart Rate

The exercise heart rates are presented in Fig. 4.2. The heart rate values tended to increase (P=0.05) during the two hours of exercise. There was however, no difference in heart rate response between TRE and CON conditions.

4.3.2. Rating of Perceived Exertion (RPE)

Ratings of perceived exertion (Borg Scale, see appendix B) are presented in Fig. 4.3. There was no difference in RPE either between treatments or with respect to time.

4.3.3. Respiratory Exchange Ratio (RER)

The values for respiratory exchange ratio (RER) are presented in Fig. 4.4. There was no difference for RER values between the TRE and CON treatments. RER values tended to decrease (P=0.06) during the two hours of exercise however this was not significant.
Fig. 4.2. Heart rate values during exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).
Fig. 4.3. Ratings of perceived exertion (Borg Scale) during exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).
Fig. 4.4. Respiratory exchange ratio values during exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).
4.4. Blood and Plasma Metabolites

4.4.1. Plasma Glucose

Plasma glucose concentrations are presented in Fig. 4.5 and Table 4.2. Plasma glucose concentration remained relatively stable during the two hour exercise period for all subjects and in all exercise trials. There was no difference for plasma glucose between the two treatments.

4.4.2. Blood and Plasma Lactate

Blood and plasma lactate concentrations are presented in Fig. 4.6 and Table 4.2. There was no difference between the TRE and CON trials for either plasma or blood lactate concentrations. The moderate increase seen in mean concentrations of plasma and blood lactate at thirty minutes of exercise (Fig 4.6) during the control trial is largely a result of one subject (see Appendix D) having a very sharp rise in lactate which is reflected by the large standard error of mean. This particular subject exercised at the same relative workload, however, she was not as familiar with riding a bike compared with the others.

4.4.3. Free Fatty Acids (FFA)

The mean plasma FFA concentrations are presented in Fig. 4.7 and Table 4.2. Plasma FFA concentrations increased (P< 0.05) during the two hour exercise period but there was no difference between the TRE and CON conditions.
Fig. 4.5. Plasma glucose concentrations during exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).
<table>
<thead>
<tr>
<th>Metabolite</th>
<th>Trial</th>
<th>PRE - EX</th>
<th>POST - EX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma Lactate</td>
<td>TRE</td>
<td>1.9 ± 0.5</td>
<td>2.6 ± 0.5</td>
</tr>
<tr>
<td>(mmol.L⁻¹)</td>
<td>CON</td>
<td>1.5 ± 0.1</td>
<td>2.6 ± 0.7</td>
</tr>
<tr>
<td>Blood Lactate</td>
<td>TRE</td>
<td>1.7 ± 0.4</td>
<td>2.2 ± 0.5</td>
</tr>
<tr>
<td>(mmol.L⁻¹)</td>
<td>CON</td>
<td>1.4 ± 0.1</td>
<td>2.5 ± 0.8</td>
</tr>
<tr>
<td>Plasma Glucose</td>
<td>TRE</td>
<td>5.08 ± 0.21</td>
<td>4.91 ± 0.23</td>
</tr>
<tr>
<td>(mmol.L⁻¹)</td>
<td>CON</td>
<td>5.16 ± 0.13</td>
<td>5.08 ± 0.47</td>
</tr>
<tr>
<td>Plasma FFA</td>
<td>TRE</td>
<td>0.33 ± 0.09</td>
<td>0.76 ± 0.16</td>
</tr>
<tr>
<td>(mmol.L⁻¹)</td>
<td>CON</td>
<td>0.27 ± 0.04</td>
<td>0.87 ± 0.30</td>
</tr>
</tbody>
</table>

**Table 4.2.** Blood and plasma metabolites before exercise (PRE-EX) and after (POST-EX) exercise under treatment (TRE) and control (CON) conditions.

Values are means ± SE, (n=5).
Fig. 4.6. Plasma and blood lactate concentrations during exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).
Fig. 4.7. Plasma free fatty acid (FFA) concentrations during exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).

* Denotes difference from 60 min, 30 min and rest.
4.5. Hormones

4.5.1. Insulin

Plasma insulin concentrations are presented in Fig. 4.8. and Table 4.3. There was no difference in plasma insulin concentrations during two hours of exercise or between the TRE and CON conditions.

4.5.2. Cortisol

Plasma cortisol concentrations are presented in Fig. 4.9 and Table 4.3. There was no difference in plasma cortisol concentrations during the two hours of exercise or between the TRE and CON conditions.

4.5.3. Catecholamines

Plasma adrenaline and noradrenaline concentrations are presented in Fig. 4.10 and 4.11 respectively. Adrenaline concentrations increased (P< 0.05) during exercise. There was no difference in plasma noradrenaline during exercise or for either adrenaline and noradrenaline between treatments.
Fig. 4.8. Plasma insulin concentrations during exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).
<table>
<thead>
<tr>
<th></th>
<th>TRIAL</th>
<th>PRE - EX</th>
<th>POST - EX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin</td>
<td>TRE</td>
<td>4.05 ± 0.47</td>
<td>2.36 ± 0.87</td>
</tr>
<tr>
<td></td>
<td>CON</td>
<td>3.79 ± 0.57</td>
<td>2.72 ± 0.96</td>
</tr>
<tr>
<td>Cortisol</td>
<td>TRE</td>
<td>609.1 ± 61.5</td>
<td>631.6 ± 54.8</td>
</tr>
<tr>
<td></td>
<td>CON</td>
<td>588.9 ± 80.6</td>
<td>758.6 ± 17.4</td>
</tr>
<tr>
<td>Adrenaline</td>
<td>TRE</td>
<td>0.16 ± 0.05</td>
<td>1.04 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>CON</td>
<td>0.09 ± 0.01</td>
<td>1.4 ± 0.5</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>TRE</td>
<td>0.83 ± 0.22</td>
<td>8.32 ± 2.64</td>
</tr>
<tr>
<td></td>
<td>CON</td>
<td>1.09 ± 0.20</td>
<td>7.84 ± 0.84</td>
</tr>
</tbody>
</table>

**Table 4.3.** Plasma hormone concentrations before (PRE-EX) and after (POST-EX) exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5)
Fig. 4.9. Plasma cortisol concentrations during exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).
Fig. 4.10. Plasma adrenaline and noradrenaline concentrations during exercise under treatment (TRE) and control (CON) conditions. Values are means ± SE, (n=5).

* Denotes difference from 60 min and rest.
4.6. Muscle Metabolites

4.6.1. Muscle Glycogen

The pre and post exercise muscle glycogen concentrations (n=2) are presented in Table 4.4. Subject three had a higher pre-exercise concentration for glycogen (721 mmol.kg dw⁻¹) under TRE conditions compared with (395 mmol.kg dw⁻¹) CON conditions. Subject five had a lower pre-exercise concentration for glycogen (401 mmol.kg dw⁻¹) under TRE conditions compared with (451 mmol.kg dw⁻¹) under CON conditions. The rate of glycogen utilisation is also presented in Table 4.5. Subject three utilised 672 mmol.kg.dw⁻¹ (TRE) compared with 326 mmol.kg dw⁻¹ (CON). Subject five utilised 265 mmol.kg dw⁻¹ (TRE) compared with 378 mmol.kg dw⁻¹ (CON).

4.6.2 Muscle Lactate

The pre and post exercise muscle lactate concentrations are presented in Table 4.5. The muscle lactate concentrations for the two subjects were similar during all exercise trials and there was no difference between the treatments.
<table>
<thead>
<tr>
<th>Subject Three</th>
<th>TRIAL</th>
<th>PRE-EX</th>
<th>POST-EX</th>
<th>Δ Glycogen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycogen</td>
<td>TRE</td>
<td>721</td>
<td>49</td>
<td>672</td>
</tr>
<tr>
<td>mmol.kg dw⁻¹</td>
<td>CON</td>
<td>395</td>
<td>69</td>
<td>326</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Subject Five</th>
<th>TRIAL</th>
<th>PRE-EX</th>
<th>POST-EX</th>
<th>Δ Glycogen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycogen</td>
<td>TRE</td>
<td>401</td>
<td>137</td>
<td>265</td>
</tr>
<tr>
<td>mmol.kg dw⁻¹</td>
<td>CON</td>
<td>451</td>
<td>73</td>
<td>378</td>
</tr>
</tbody>
</table>

**Table 4.4.** Muscle glycogen concentrations before (PRE-EX) and after (POST-EX) exercise and muscle glycogenolysis (Δ) under (TRE) and (CON) conditions.
<table>
<thead>
<tr>
<th>Subject Three</th>
<th>TRIAL</th>
<th>PRE - EXERCISE</th>
<th>POST - EXERCISE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactate</td>
<td>TRE</td>
<td>3.3</td>
<td>3.2</td>
</tr>
<tr>
<td>mmol.kg dw⁻¹</td>
<td>CON</td>
<td>2.5</td>
<td>2.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Subject Five</th>
<th>TRIAL</th>
<th>PRE - EXERCISE</th>
<th>POST - EXERCISE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactate</td>
<td>TRE</td>
<td>3.5</td>
<td>4.7</td>
</tr>
<tr>
<td>mmol.kg dw⁻¹</td>
<td>CON</td>
<td>4.4</td>
<td>4.7</td>
</tr>
</tbody>
</table>

Table 4.5. Muscle lactate concentrations before (PRE-EX) and after (POST-EX) under (TRE) and (CON) conditions.
CHAPTER FIVE

DISCUSSION

The purpose of the present study was to determine whether being amenorrheic altered the pattern of energy metabolism during sub-maximal endurance exercise. This was investigated by raising the concentration of oestradiol in amenorrheic athletes to concentrations similar to those of their eumenorrheic counterparts.

The administration of oestradiol using the medium dose patch significantly increased the resting concentrations of oestradiol from $81 \pm 7$ to $114 \pm 17$ pmol. l$^{-1}$. The expectation was that oestradiol concentrations would be raised to levels similar to those that occurred during the follicular phase of the menstrual cycle (Balfour and Heel, 1990). Such moderate elevations of oestradiol were unlikely to be associated with side-effects such as fluid retention, which would have jeopardised the continued participation of the subjects in the study. The mean oestradiol concentrations after three weeks oestradiol therapy in the present study ($114 \pm 17$ pmol. l$^{-1}$) were similar to the mean reported oestradiol levels reported for eumenorrheic women ($153.4 \pm 71.3$ pmol. l$^{-1}$) in the follicular phase (De Souza et al., 1990). These concentrations contrast with those seen in eumenorrheic women in the mid-luteal phase where oestradiol levels average 549.2 pmol. l$^{-1}$. It is important to note that in the present study the mean of the differences in oestradiol values between the two trials was 33.12 pmol. l$^{-1}$ whereas the difference in oestradiol values between the two phases of the menstrual cycle in De Souza et al., (1990) study was 395.8 pmol. l$^{-1}$. This may help to explain
why in the present study there was no significant difference in the way substrates were metabolised during two hours of sub-maximal exercise under treatment and control conditions.

It has been suggested that progesterone, the other ovarian steroid, exerts an anti-oestrogenic effect and that it is the ratio of oestradiol to progesterone that determines the metabolic action of oestradiol (Kenagy et al., 1981; Puah and Bailey, 1985). In the present study, despite elevating oestradiol, the ratio of oestradiol to progesterone was not different between the treatment (TRE) and control (CON) conditions. The unchanged ratio of the two hormones may help to explain why there was no difference in energy metabolism under TRE and CON conditions.

In the present study there was no difference in any of the parameters of exercise intensity when comparing TRE with CON. The elevations in heart-rate during exercise, were similar for the two trials, in agreement with studies conducted to compare the mid-luteal with the early-follicular phases of the menstrual cycle (De Souza et al., 1990; Jurowski et al., 1981; Nicklas et al., 1989). Ratings of perceived exertion (RPE) in the present study were not different between TRE and CON in accord with the studies by Stephenson et al. (1982), who observed no difference in RPE at the same workload during five different phases of the menstrual cycle, and De Souza et al., (1990) who observed no difference for RPE between the mid luteal and early follicular phase of the menstrual cycle during sub-maximal and maximal exercise.
Blood glucose is normally the sole source of energy for the central nervous system and several other tissues and therefore homeostasis is directed towards maintaining blood glucose concentration within a narrow range (Bjorkman, 1986). Maintenance of blood glucose during exercise is predominantly due to glycogen breakdown to glucose in liver and the production of glucose via gluconeogenic precursors. The extent to which oestradiol affects these two processes directly is not well understood. The concentration of glucose in blood plasma in the present study was not altered by the change in oestradiol levels. Bonen et al. (1991) who observed no difference in glucose concentrations during exercise between the luteal and follicular phases of the menstrual cycle. These results, however, contrast with those of Lavoie et al. (1987) who observed lower blood glucose concentrations at 70 and 90 minutes of moderate intensity exercise during the luteal phase compared with the follicular phase of the menstrual cycle. In the study by Lavoie et al. (1987), subjects fasted overnight after adhering to a 24-hour low-carbohydrate diet, and are likely to have had a lower pre-exercise liver glycogen content than in the present study. Gluconeogenesis would therefore be an important mechanism to maintain blood glucose. The authors hypothesised that oestradiol may have exerted its effect by inhibiting gluconeogenesis, thereby lowering blood glucose concentrations. The present study is inconclusive with regard to the effects of oestradiol administration on the homeostasis of blood glucose, since subjects were glycogen replete prior to exercise and the blood glucose concentrations were maintained throughout exercise.

In the present study the lactate response to exercise was similar between TRE and CON which contrasts the findings of Jurowski et al. (1981) and Lavoie et al. (1987) who observed lower concentrations of lactate in the luteal phase of the menstrual cycle when oestradiol is high. The differences in these findings compared with the present study may be due to the different exercise protocols used by Jurowski et al. (1981) and the different pre-exercise diet regimes used by Lavoie et al. (1987).
Jurowski et al. (1981) tested trained athletes during heavy (90% VO$_2$ max) and maximal (100% VO$_2$ max) exercise and reported higher lactate concentrations in the follicular phase compared with the luteal phase of the menstrual cycle. These authors postulated that oestrogen mediated a shift towards FFA metabolism in the luteal phase, which even during intense exercise resulted in decreased lactate concentrations. However, during exercise at 100% VO$_2$ max, it is unlikely that there would be any shift towards fat metabolism (Powers and Howley, 1993). Indeed, Robertson and Higgs (1983) observed no difference in blood lactate during treadmill running at 90% and 100% VO$_2$ max during the mid-follicular and mid-luteal phases and day one of menses.

It is well documented that the metabolic effect of oestradiol is to cause a shift in metabolism during exercise at lower intensities towards FFA metabolism through increased lipid synthesis and enhanced lipolysis in muscle and adipose tissue (Bunt, 1990; Hackney et al., 1990; Jurowski et al., 1981). In the present study there was no difference in the resting or exercising concentrations of plasma FFA between the TRE and CON trials. It appears unlikely that these results would have represented increased muscle triglyceride (TG) lipolysis and a concurrent increase in fat oxidation, i.e. increased turnover of FFA, without altering plasma FFA concentrations. If such a shift towards increased muscle TG utilisation had occurred, then RER values would be expected to have been lower for TRE which was not the case. This similarity in FFA concentrations between TRE and CON are in agreement with others whereby there was no difference in resting plasma FFA (Bonen et al., 1991) or exercising plasma FFA concentrations (Lavoie et al., 1987) during the luteal phase compared with the follicular phase of the menstrual cycle.

Oestradiol may alter metabolism by exerting an influence on other regulatory hormones. In the present study, the effects of oestradiol administration did not have a measurable effect on plasma concentrations of insulin, cortisol or catecholamine
responses. Amenorrheic women are observed to have higher resting cortisol levels compared with eumenorrheic women (De Souza et al., 1988; Ding et al., 1988; Kanaley et al., 1992). The cortisol levels in the present study are similar to those observed by others for amenorrheic women. The elevated cortisol concentrations in amenorrheic women may be associated with disturbances in the hypothalamic-pituitary-adrenal function (Kanaley et al., 1992) however the site(s) of the disturbance is/are yet to be determined. The difference in cortisol levels between amenorrheic and eumenorrheic women does not appear to be related to changes in oestradiol concentrations because there has been no difference observed in cortisol levels during the early follicular, late follicular and mid luteal phase of the menstrual cycle (Kanaley, 1992). The concentration of cortisol is observed to increase during moderate exercise and exert metabolic actions by antagonising the effects of insulin (Martin and Wahren, 1993). A similar trend in cortisol concentrations during the two hours of sub-maximal exercise was observed in the present study however the increases in TRE and CON were not statistically significant.

During exercise insulin concentrations commonly decline and catecholamine and glucagon concentrations increase resulting in the stimulation of glycogenolysis, gluconeogenesis and lipolysis (Martin and Wahren, 1993). In the present study neither the exercise stimulus nor the oestradiol therapy had any effect on insulin response. These results are similar to those observed by Bonen et al. (1991). It is possible that no significant decrease in insulin concentrations was observed over the two hour exercise period because of the small sample size. Oestradiol has been observed to increase the molar ratio of insulin to glucagon when moderate to high doses (10 or 100 nmol/kg/day) were infused but not when using low doses (1 nmol/kg/day) (Mandour et al., 1977). The magnitude to which these hormones exert any metabolic action appears to be dependent on the relative molar ratio between insulin and glucagon rather than the absolute concentrations of either hormone (Mandour et al., 1977). An increase in the insulin to glucagon molar ratio is observed to increase
hepatic lipogenesis and inhibit gluconeogenesis (Mandour et al., 1977). In the present study, it is unknown the effect oestradiol had on the molar ratio of insulin to glucagon because plasma glucagon was not measured. However, given the lack of differences between treatment and control conditions, it is unlikely that the ratio of insulin to glucagon would have changed significantly.

The observed increase in plasma catecholamines during the two hours of exercise was expected as exercise is a strong stimulus for catecholamine release. There was however no difference in adrenaline or noradrenaline responses under different oestradiol concentrations which is in contrast with the observations of Sutton et al. (1980) who reported higher adrenaline concentrations when oestradiol concentrations are low. Increased concentrations of adrenaline result in an increase in circulatory glucose due to an increase in glycogenolysis (Chasiotis et al., 1983). Evidence to support this is the increase in glucose and lactate concentrations during the follicular phase of the menstrual cycle when adrenaline concentrations were elevated (Sutton et al., 1980). In the present study despite an increase in adrenaline during exercise there was no change in either plasma glucose or lactate concentrations.

Initial muscle glycogen stores are thought to be a limiting factor in the ability to sustain endurance exercise (Bergstrom et al., 1967). In the present study permission to obtain muscle samples was given only by two of the subjects and therefore the interpretation of the results is limited. Subject number three had a greater muscle glycogen content at rest for TRE compared with CON, which is similar to the findings of Hackney, (1990) who observed greater resting muscle glycogen content during the menstrual cycle when oestradiol concentrations are high. This subject also utilised more glycogen during the two hour exercise period when pre-exercise muscle glycogen levels were high. It is well documented that an elevated pre-exercise glycogen content, increases the rate of muscle glycogen utilisation during sub-maximal exercise (Chesley et al., 1995; Hargreaves et al., 1995; Hespel and Richter,
Subject number five, had an elevated pre-exercise content for muscle glycogen under the CON treatment compared with the TRE. During exercise this subject utilised more glycogen during the control trial and once again this may be related to pre-exercise muscle glycogen levels. Muscle lactate values for the same two subjects were also measured. When resting muscle glycogen content was higher corresponding with greater utilisation there also appeared to be higher muscle lactate levels, as would be expected.

It is known that when muscle glycogen availability is increased, there is an increase in muscle glycogenolysis and that oestradiol exerts an effect on metabolism by increasing resting muscle glycogen content. In addition, oestradiol promotes the release and utilisation of lipids. What is not known is which metabolic pathway is favoured under the control of oestradiol during exercise. It is interesting to point out that the one subject who showed a large increase in plasma oestradiol also showed a lower RER during exercise suggesting the lipid pathway is favoured.
CHAPTER SIX

CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE RESEARCH

In the present study moderate elevation of plasma oestradiol concentrations in amenorrheic athletes did not alter substrate utilisation during two hours of exercise. It therefore appears that raising oestradiol concentration to that achieved in the present study is not advantageous for amenorrheic athletes during two hours of sub-maximal exercise.

It may, however, be possible that some plasma oestradiol threshold needs to be exceeded or the ratio of oestradiol to progesterone to be altered before differences in energy metabolism can be observed. It is also possible that under other exercise performance parameters, such as exercise until exhaustion, an altered metabolic response may be observed.

Recommendations for further studies include the administration of higher doses of oestradiol and changing the exercise performance parameters, for example, exercise to exhaustion.
REFERENCES


Hackney, A.C. Effects of the menstrual cycle on resting muscle glycogen content. 
*Hormone Metabolism Research, 22:647, 1990.*


APPENDIX A

Subject Correspondence
SUBJECT INFORMATION SHEET

To delay the onset of fatigue in endurance events it is advantageous to prolong muscle glycogen depletion. Oestradiol (the female sex hormone) has been shown to increase muscle glycogen content and increase the availability of fat as a fuel source therefore delaying the onset of fatigue. Initially you will answer questionnaires in relation to your menstrual cycle, physical training, cardiovascular and blood sampling risk factors. All responses will be numerically coded and remain confidential. Measurements will be taken for height, weight, and body composition. Body composition will be determined by taking skin fold measurements at eight different sites. To assess your levels of aerobic fitness an incremental exercise test until exhaustion will be performed on a cycle ergometer.

The next two visits to the lab will consist of an exercise trial which will be performed under a placebo and treatment condition. It is very important that you arrive at the laboratory well rested and in a fasted state prior to each trial. In order to ensure this, you need to avoid strenuous exercise twenty four hours prior to the trial and refrain from eating breakfast. Dietary guidelines will be given for you to follow in the three days prior to each test and once again it is very important that they are adhered to. The exercise trial consists of cycling for two hours at 70% max VO₂. Prior to the exercise a small catheter will be placed into an arm vein. The catheter consists of a needle and teflon tubing. The tubing is fed over the top of a needle (which has punctured the vein) and into the vein. A tap (stopcock) is placed into the tubing so the flow of blood along the tubing can be altered at will. This procedure allows the taking of multiple blood samples without the need for multiple venipuncture (puncturing of the vein). Each time a blood sample is taken a small volume of sterile heparinised saline will be injected to clear the catheter and keep patent. Catheterisation of subjects is slightly discomforting and can lead to the possibility of bruising and infection. In our experience this occurs rarely. Prompt action will alleviate any serious medical problem.

In addition, before and after exercise we will take a small sample of muscle from the thigh muscle using a special needle biopsy technique. Two small incisions, one for each sampling time will be made in the skin overlying the muscle under a local anaesthetic by a doctor. A biopsy needle is inserted into the belly of the muscle and a piece of muscle about the size of a rice grain is removed. At this time you may experience a pressure in the muscle and a tendency for the muscle to cramp but this lasts only a couple of seconds. The incision is closed with special closures and will heal over the next week. It is common to experience some local soreness in the next 24-48 hours. In extreme cases local bruising and swelling may occur; however, the use of sterile procedures and the application of an ice pack and pressure bandage minimises the chance of this. During the exercise you will be wearing a mouthpiece/valves (similar to a snorkel) system to collect the air you have expired. We will also be monitoring your heart rate using a heart rate monitor. The results of this study will provide important new information on the metabolic responses in ammenorrheic athletes when administered oestradiol during prolonged exercise and the possible implications for performance.

Could you please answer the attached questionnaires and if you are happy with everything sign the consent form. I remind you that you are free to withdraw from any phase of the study at anytime and that all your results are strictly confidential. Please dont hesitate to ask questions if you have any. Thank you for agreeing to assist with us in our research.
QUESTIONNAIRE

1. Name:

2. Address

Postcode:

3. Telephone No: (B) (H)

4. Date of Birth:

5. Are you currently using oral contraceptive pills?

6. Have you ever used oral contraception, if so for how long where you taking them for and how long has it been since you stopped taking it?

7. How old were you when you first menstruated?

......................years......................months.

8. Would you describe your menstrual cycle as being regular (10-12 cycles per year)?

Yes [ ] No [ ]

9. If you answered no to question eight, how many times would you menstruate per year and how long has it been since you last menstruated?

..........................................................<br>..........................................................<br>..........................................................<br>..........................................................<br>..........................................................<br>..........................................................<br>..........................................................<br>

10. Have you ever had any irregularities with your menstrual cycle before you began athletic training? If yes, please explain.

..........................................................<br>..........................................................<br>..........................................................<br>..........................................................<br>..........................................................<br>..........................................................<br>..........................................................<br>

11. How old were you when you first began to train for triathlons?

..........................................................years.
12. What form of exercise were you participating in before triathlon training if any at all

13. How many hours are you currently training per week?

14. What is the distance that you would cover on average during one week's training?

Running: km
Swimming: km
Cycling: km

15. Is there any other form of training e.g. weights that you do each week? If so, what form does this training take and how much time is spent doing it?

16. How many hours sleep do you get on average per night?

17. Describe a typical day's diet including all food, beverages and quantities.

Breakfast:

Lunch:

Dinner:

Snacks:
## HEALTH AND FITNESS SERVICES
### RISK FACTOR ASSESSMENT QUESTIONNAIRE

<table>
<thead>
<tr>
<th>NAME:</th>
<th>DATE:</th>
<th>ADDRESS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE: (Years)</td>
<td>SEX: M/F</td>
<td>WEIGHT: (kg)</td>
</tr>
<tr>
<td>HEIGHT: (cm)</td>
<td>POSTCODE:</td>
<td>FAX:</td>
</tr>
<tr>
<td>TELEPHONE: (Work)</td>
<td>ADDRESS:</td>
<td>TELEPHONE: (Home)</td>
</tr>
</tbody>
</table>

### MEDICAL HISTORY:
In the past have you ever had (tick No or Yes)

- Stroke
- Myocardial infarction (heart attack)
- Angina Pectoris
- Heart Murmur
- Heart Rhythm Disturbance
- Rheumatic Fever

List any prescribed medications being taken

- NO
- YES

- NO
- YES

- NO
- YES

- NO
- YES

Allergies: Do you have any allergies

If yes, give details:

### SYMPTOMS DURING OR AFTER EXERCISE
As a result of exercise, have you ever experienced any of the following:

- Pain or discomfort in the chest, back, arms, or jaw
- Severe shortness of breath or problems with breathing during mild exertion
- Dizziness, nausea or fainting

Cardiovascular Risk Factors:
Do you have (tick No, Yes or circle ?)

- High Blood Pressure
- High Blood Cholesterol/Triglycerides
- Smoking Habit
- Diabetes
- Do you drink alcohol regularly

- NO
- YES
- DON'T KNOW

Ex. Smoker Average/day...

Average/day...
FAMILY MEDICAL HISTORY:

Have members of your immediate family ever had any of the following conditions: (tick No, Yes or circle ?). If you answer Yes or ?, write beside this the member of the family affected (F = father, M = mother, B = brother, S = sister, GM = grandmother, GF = grandfather).

<table>
<thead>
<tr>
<th>Condition</th>
<th>NO</th>
<th>YES</th>
<th>?</th>
<th>FAMILY MEMBER</th>
<th>AGE (Years)</th>
<th>ALIVE NOW? (Y/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial infarction (heart attack)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angina Pectoris</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Blood Pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Blood Cholesterol/Triglycerides</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PERSONAL LIFESTYLE:

A. Exercise
List the sports, exercises or physically active hobbies (e.g. gardening or playing with the kids) that you are currently engaged in:

<table>
<thead>
<tr>
<th>Sports/Activity</th>
<th>Day(s) of week</th>
<th>Time of the day</th>
<th>Approx. duration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sa-Su-Mo-Tu-We-Smith</td>
<td>eg. 6 p.m.</td>
<td>eg. 30 minutes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B. Nutrition
List a typical day's eating pattern.

<table>
<thead>
<tr>
<th>Breakfast</th>
<th>Lunch</th>
<th>Dinner</th>
<th>Snacks</th>
<th>Drinks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C. Rest/Recreation
How many hours sleep do you usually have? ________________ hours.

On average how much time do you spend each day on passive hobbies or just relaxing ________________ minutes/hours.

Do you feel that you usually get enough restful sleep and time to relax? Yes No

CLIENT DECLARATION

I declare that the above information is to my knowledge true and correct, and that I have not omitted any information that is requested on this form

S

CLEARANCE TO UNDERGO AN EXERCISE TEST

This person has been cleared to undergo a fitness test:

☐: Without medical supervision
☐: With medical supervision
☐: A fitness test is not advisable at this time

Signed: Dr/Mr/Mrs/Ms ____________________________

(Circle appropriate title: physician exercise physiologist)
VICTORIA UNIVERSITY OF TECHNOLOGY

STANDARD CONSENT FORM FOR SUBJECTS INVOLVED IN EXPERIMENTS

CERTIFICATION BY SUBJECT

I, .......................................................... of ..........................................................
certify that I have the legal ability to give valid consent and that I am voluntarily giving
my consent to participate in the experiment entitled:


being conducted at Victoria University of Technology by:


I certify that the objectives of the experiment, together with any risks to me associated
with the procedures listed hereunder to be carried out in the experiment, have been
fully explained to me by:

Miss Sally Clark

and that I freely consent to participation involving the use on me of these procedures.

Procedures

Maximal aerobic capacity testing                                   Underwater weighing technique
Blood Sampling by catheterisation                                  Muscle sampling by needle biopsy
Answering of Questionnaires

I certify that I have had the opportunity to have my questions answered and that I
understand that I can withdraw from the experiment at any time and that this
withdrawal will not jeopardise me in any way.

I have been informed that the confidentiality of the information I provide will be
safeguarded.

Signed: .......................................................

)  )
Witness other than the experimenter:  ) Date: ..........................

)  )
APPENDIX B

Description of Skinfold Sites
Borg Scale
Body Mass Index Equation
Skinfold Sites

**Bicep** - The skinfold is raised with the left thumb and index finger on the marked mid-acromiale-radiale line so that the fold runs vertically. The subject stands with the arm relaxed and extended, and the fold is located on the most anterior aspect of the surface of the right arm.

**Tricep** - The skinfold is raised with the left thumb and the index finger on the marked posterior mid-acromiale-radiale line. The fold is vertical and parallel to the line of the upper arm. The skinfold is taken on the most posterior surface of the arm over the triceps muscle when viewed from the side.

**Subscapular** - The left thumb palpates the inferior angle (apex) of the scapula and with the thumb still in position the index finger reaches over the top of the thumb which is then reposition to raise a skinfold just inferior to and slightly lateral to the apex. This fold runs obliquely downward toward the lateral aspect of the body.

**Suprailiac** - This skinfold is raised immediately superior to the iliac crest on the ilio-axilla line. Palpate the superior edge of the right ilium of the subject using the fingers of the right hand. Align the fingers with the ilio-axilla. Using the left hand raise the skinfold immediately above the right hand. The fold runs slightly downwards toward the medial aspect of the body.

**Abdominal** - This is a vertical fold raised 5 cm from the right hand of the mid point of the navel.

**Thigh** - The fold is raised parallel to the long axis of the femur at the mid-point of the distance between the inguinal fold and the superior anterior border of the patella.

**Calf** - With the subject seated a vertical fold is raised on the medial aspect of the calf at a level where it has maximal circumference.
BORG SCALE

6
7  Very Very Light
8
9  Very Light
10
11  Fairly Hard
12
13  Somewhat Hard
14
15  Hard
16
17  Very Hard
18
19  Very Very Hard

Body Mass Index Equation

Body mass (kg) \div \text{The square of the height (m)}
APPENDIX C

Analytical Techniques
MUSCLE LACTATE DETERMINATION

Principle

Lactate + NAD\(^+\) \rightarrow pyruvate + NADH + H\(^+\)

\[\text{lactate dehydrogenase}\]

Pyruvate + Hydrazine \rightarrow pyruvate hydrazone

MUSCLE GLYCOGEN DETERMINATION

Principle

Glucose + ATP \rightarrow ADP + G-6-P

\[\text{hexokinase}\]

G-6-P + NADP \rightarrow 6-P-Gluconolactone + NADPH

\[\text{G-6-P dehydrogenase}\]

* 500 and 50μM lactate standards and 500 and 250μM glucose standards are used in the assay

* assays are run with a set of NADH standards (50, 100, 200 400μM)
  - read absorbance of these on spectrophotometer at 340 nm and adjust concentration according to the MEC (× 10^{-3}) (6220)
  - record actual standard concentration and construct a standard curve (NADH concentration and fluorescence).

* if the metabolite standard fluorescence's are within 10% error of predicted standard fluorescence, the assay is successful.
BLOOD AND PLASMA LACTATE

Principle:- The enzyme lactate dehydrogenase (LDH) catalyses the transfer of hydrogen from the cofactor NADH to pyruvic acid to produce lactic acid. However, the equilibrium highly favors the reduction of pyruvic acid:

\[
\text{LDH} \\
\text{Lactic acid + NAD}^+ \rightleftharpoons \text{Pyruvic acid + NADH}
\]

\[K_{eq} = 3.6 \times 10^{11} \text{ M}^{-1}\]

In the presence of an excess of the cofactor NAD+ and lactate dehydrogenase activity, and at a pH of 9.6, nearly all of the lactate, is deproteinized whole blood, is converted to pyruvate. To ensure the reaction goes to completion, pyruvic acid, in the presence of hydrazine, is removed by converting it to pyruvatehydrazone. The appearance of NADH yields an observable method to quantify the concentration of lactate originally present. The concentration of NADH was measured spectrophotometrically at wavelength of 340 nm using a spectrophotometer (Shimadzu UV - 120-02) in conjunction with flow cell apparatus (Sigma Technical Bulletin, No 826 UV, Oct 1986).

A set of standards ranging in concentration from 1mM to 10mM was run with each analysis in conjunction with a reagent blank.
Calculations for Determining Metabolite Concentrations

Calculation for the metabolites is as follows:

\[
\text{no. moles} = \frac{\text{sample fluorescence}}{\text{standard Fluores.}} \times \text{Std. Molarity(M)} \times \text{vol. of sample}
\]

You must correct for the fact that you have 250 µl of extract one, which you then transferred 200µl to 50µl of KHCO₃ to make 250µl of extract two. You must also take into consideration the weight of the extract. Examples of a method for calculation is as follows:

CALCULATIONS TO DETERMINE MUSCLE GLYCOGEN CONCENTRATION

Extraction

A known weight of muscle was placed into 0.5 ml of 2M HCL. This was cooked for two hours. After cooking 1.5ml of 0.667M NaOH was added. Therefore, a known weight of muscle was extracted in 2 ml of fluid. For glycogen assay the standard was 0.5 mM glucose.

Calculations

10µl of standard contains \(10 \times 10^{-6} \times 0.5 \times 10^{3}\) moles of glucose and gives \(\times\) fluorescence units (FU).

10µl of sample extract contains \(y\) moles and produces \(z\) FU. Therefore

\[y = \frac{z}{\times} \times 10 \times 10^{-6} \times 500 \times 10^{-6}\] moles.

Muscle sample contains \(y \times 200\) moles / weight of muscle.

Convert units to mmol.kg⁻¹ dry weight.
APPENDIX D

Individual Data
<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Prog (nmol/L)</th>
<th>Oestradiol (nmol/L)</th>
<th>Cortisol (nmol/L)</th>
<th>Insulin (mU/ml)</th>
<th>Noradren (nmol/L)</th>
<th>Adren (nmol/L)</th>
<th>HFFA (mmol/L)</th>
<th>Pla Lac (mmol/L)</th>
<th>Bid Lac (mmol/L)</th>
<th>Glucose (mmol/L)</th>
<th>H.R.</th>
<th>P.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.5</td>
<td>1.7</td>
<td>2.3</td>
<td>2.8</td>
<td>0.1</td>
<td>0.2</td>
<td>0.27</td>
<td>1.79</td>
<td>1.43</td>
<td>5.4</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>30</td>
<td>0.6</td>
<td>1.8</td>
<td>2.8</td>
<td>3.8</td>
<td>0.2</td>
<td>0.3</td>
<td>0.315</td>
<td>1.82</td>
<td>1.44</td>
<td>5.4</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>60</td>
<td>0.7</td>
<td>1.9</td>
<td>3.2</td>
<td>4.5</td>
<td>0.3</td>
<td>0.4</td>
<td>0.407</td>
<td>2.26</td>
<td>1.82</td>
<td>5.4</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>90</td>
<td>0.8</td>
<td>2.0</td>
<td>3.8</td>
<td>5.0</td>
<td>0.5</td>
<td>0.5</td>
<td>0.843</td>
<td>2.09</td>
<td>1.58</td>
<td>5.4</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>120</td>
<td>0.9</td>
<td>2.1</td>
<td>4.4</td>
<td>5.6</td>
<td>0.7</td>
<td>0.6</td>
<td>1.111</td>
<td>2.02</td>
<td>1.45</td>
<td>5.4</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>150</td>
<td>1.0</td>
<td>2.2</td>
<td>4.9</td>
<td>6.2</td>
<td>0.9</td>
<td>0.7</td>
<td>0.067</td>
<td>1.77</td>
<td>1.28</td>
<td>5.4</td>
<td>1.3</td>
<td>1.3</td>
</tr>
</tbody>
</table>

**Physiological Parameters**

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Control</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>30</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>60</td>
<td>1.2</td>
<td>1.2</td>
</tr>
<tr>
<td>90</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>120</td>
<td>1.4</td>
<td>1.4</td>
</tr>
</tbody>
</table>

**Subject One**
<table>
<thead>
<tr>
<th>Hormones</th>
<th>FFA (mmol/L)</th>
<th>Plac Lac (mmol/L)</th>
<th>Glucose (mmol/L)</th>
<th>Physiological Parameters</th>
<th>Time</th>
<th>Treatment</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prog (nmol/L)</td>
<td>0.5</td>
<td>102.47</td>
<td>574.359</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oestradiol (pmol/L)</td>
<td>0.5</td>
<td>1.06</td>
<td>5.487</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortisol (nmol/L)</td>
<td>0.5</td>
<td>3.3</td>
<td>5.163</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noradren (nmol/L)</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adren (nmol/L)</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin (uU/ml)</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noradren (nmol/L)</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma/Blood Metabolites</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FFA (mmol/L)</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plac Lac (mmol/L)</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>physiological Parameters</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.5</td>
<td>3.2</td>
<td>7.072</td>
<td>110</td>
<td>33</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TIME</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>90</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>120</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Plasma Blood Metabolites

- **Lac (mmol/L)**
  - Treatment: 2.5
  - Control: 3.945
- **Gly (mmol/kg/dw)**
  - Treatment: 394.5
  - Control: 68.65
- **Muscle Prog (nmol/L)**
  - Treatment: 0.8
  - Control: 0.4
- **Oestradiol (pmol/L)**
  - Treatment: 72.52
  - Control: 100.47
- **Cortisol (nmol/L)**
  - Treatment: 561.65
  - Control: 420.11
- **Insulin (uU/ml)**
  - Treatment: 3.256
  - Control: 2.514
- **Noradren (nmol/L)**
  - Treatment: 1.64
  - Control: 0.45
- **Adren (nmol/L)**
  - Treatment: 0.11
  - Control: 0.45
- **FFA (mmol/L)**
  - Treatment: 0.367
  - Control: 0.367
- **Plac Lac (mmol/L)**
  - Treatment: 0.851
  - Control: 0.985
- **Glucose (mmol/L)**
  - Treatment: 5.48
  - Control: 6.46

Physiological Parameters

- **Time (min)**
  - Control: 0
  - Treatment: 0

Subject THREE
<table>
<thead>
<tr>
<th>Hormones</th>
<th>Plasmatic Metabolites</th>
<th>Physiological Parameters</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prog (nmol/L)</td>
<td>Oestradiol (pmol/L)</td>
<td>Cortisol (nmol/L)</td>
<td>Insulin (uU/ml)</td>
</tr>
<tr>
<td>1.04</td>
<td>1.46</td>
<td>0.63</td>
<td>2.91</td>
</tr>
<tr>
<td>1.14</td>
<td>1.47</td>
<td>0.55</td>
<td>3.469</td>
</tr>
<tr>
<td>0.08</td>
<td>0.87</td>
<td>0.124</td>
<td>1.74</td>
</tr>
<tr>
<td>0.08</td>
<td>0.124</td>
<td>0.167</td>
<td>4.579</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FFA (mmol/L)</th>
<th>Plac Lac (mmol/L)</th>
<th>Bid Lac (mmol/L)</th>
<th>Glucose (mmol/L)</th>
<th>H.R.</th>
<th>P.E.</th>
<th>P.O.</th>
<th>N.R.</th>
<th>V.O.</th>
<th>V.C02</th>
<th>V.O2</th>
<th>V.E</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.00</td>
<td>0.224</td>
<td>0.146</td>
<td>5.41</td>
<td>0.91</td>
<td>0.924</td>
<td>0.924</td>
<td>1.3</td>
<td>0.96</td>
<td>0.96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.42</td>
<td>5.61</td>
<td>5.86</td>
<td>5.9</td>
<td>1.14</td>
<td>0.94</td>
<td>0.94</td>
<td>1.12</td>
<td>0.94</td>
<td>0.94</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Plasma/Blood Metabolites</th>
<th>physiological Parameters</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>H.R.</td>
<td>P.E.</td>
<td>P.O.</td>
</tr>
<tr>
<td>1.04</td>
<td>1.47</td>
<td>1.2</td>
</tr>
<tr>
<td>1.14</td>
<td>1.47</td>
<td>1.2</td>
</tr>
<tr>
<td>Muscles</td>
<td>Glycogen (mmol/kg/dw)</td>
<td>Oestradiol (nmol/L)</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td></td>
<td>4.35</td>
<td>2.3</td>
</tr>
<tr>
<td></td>
<td>451</td>
<td>4.3</td>
</tr>
<tr>
<td></td>
<td>73.9</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>40.169</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>0.315</td>
<td>7.7</td>
</tr>
<tr>
<td></td>
<td>136.6</td>
<td>1.2</td>
</tr>
</tbody>
</table>

**Note:** The table contains data for various physiological parameters including hormones, muscle glycogen levels, and plasma/blood metabolites. The data is presented in a tabular format with columns for different parameters and rows for various time points and treatment conditions. The table is labeled with Subject Five, indicating it is part of a larger study or experiment.
Subject One
New Reference Ranges from 1/1/1993

<table>
<thead>
<tr>
<th>Condition</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-Menopause (F)</td>
<td>&gt; 2.2</td>
<td>&lt; 5.2</td>
</tr>
<tr>
<td>LH IU/mL</td>
<td>2.3 - 6.2</td>
<td>7.4 - 9.0</td>
</tr>
</tbody>
</table>

** Gonadotropins Reference Range from 1/1/1993**

- FSH: 10 - 40 IU/mL
- LH: 1 - 10 IU/mL

**Luteinizing Hormone**

- Normal: 6 - 20 IU/mL
- Elevated: > 20 IU/mL

**Prolactin**

- Normal: 5 - 50 pg/mL
- Elevated: > 50 pg/mL

**Human Chorionic Gonadotropins**

- Normal: 1 - 2 IU/mL

**Result Units**

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>LH</td>
<td>5.6</td>
<td>2.3 - 6.2</td>
</tr>
<tr>
<td>FSH</td>
<td>10.5</td>
<td>10 - 40</td>
</tr>
<tr>
<td>LH</td>
<td>4.8</td>
<td>1 - 10</td>
</tr>
</tbody>
</table>

**Date:** 03/08/1993 Time 11:40 HR

**Subject:** Two

**Instruction:** Feb 1 1994 11:22 am Single Report
### Gonadotropin Luteinizing (FSH)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-Menopause</td>
<td>0.9-9.0</td>
<td>&gt;7.4</td>
</tr>
<tr>
<td>LH/LH Mu/ml</td>
<td>1.2-11</td>
<td>1.2-11</td>
</tr>
<tr>
<td>Female FSH Luteal</td>
<td>0.9-5.5</td>
<td>2.3-8.8</td>
</tr>
<tr>
<td>Female FSH Follicular</td>
<td>2.2-6.2</td>
<td>2.2-6.2</td>
</tr>
</tbody>
</table>

### Progesterone

<table>
<thead>
<tr>
<th>Condition</th>
<th>Normal</th>
<th>Gestational Reference Range</th>
<th>&lt; 1.95 mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>Late Pregnancy</td>
<td>45-450</td>
<td>1.95-11.80 mg/dl</td>
<td>1.95-11.80</td>
</tr>
<tr>
<td>Early Pregnancy</td>
<td>36-360</td>
<td>1.95-11.80 mg/dl</td>
<td>1.95-11.80</td>
</tr>
</tbody>
</table>

### Instructon

- Use the reference ranges above for women in late pregnancy.
- Use the gestational reference range for women in early pregnancy.

**Reference:**

- The reference ranges are based on the National Committee for Clinical Laboratory Standards (NCCLS) guidelines.
- Consult with a healthcare provider for specific guidance.

**Note:**

- The reference ranges may vary depending on the laboratory and the specific test methods used.
- Results should be interpreted in the context of the patient's clinical history and other test results.

**Date:** 11/3/1993

---

**FILED INSTRUCTIONS:**

- Effective: Oct 13 1993
- Replaces previous page 1/93

---

**Subject:**

- Include all relevant patient information and test results.
- Follow up with the patient as indicated.

---

**Reference:**

- The reference ranges are based on the National Committee for Clinical Laboratory Standards (NCCLS) guidelines.
- Consult with a healthcare provider for specific guidance.

**Note:**

- The reference ranges may vary depending on the laboratory and the specific test methods used.
- Results should be interpreted in the context of the patient's clinical history and other test results.

**Date:** 11/3/1993

---

**FILED INSTRUCTIONS:**

- Effective: Oct 13 1993
- Replaces previous page 1/93

---

**Subject:**

- Include all relevant patient information and test results.
- Follow up with the patient as indicated.
The Interpretable Interpretation of Isolated Testosterone Levels in the
Male

Post-Menopause
60 - 200 µmol/L

Post-Menopause
> 200 µmol/L

榈
35 - 700 µmol/L

Female

Normalization Reference Range
0.9 - 9.0 µmol/L

Male

12 - 7.4 µmol/L

< 12 µmol/L

Luteal
1.2 - 5.5

Colilicin (E)
2.3 - 8.6

Colilicin (F)

progesterone

Result:

Units

Date: 26,11,1993
Time: 13:10

Result:

Units

Date: 26,11,1993
Time: 13:10

[Signature]

Note: See below

117
misleading.

The interpretation of isolated ASTrogan levels in the

<table>
<thead>
<tr>
<th>Gender</th>
<th>Reference Range from 1/1/1993</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>0.9 - 6.0</td>
</tr>
<tr>
<td>Female</td>
<td>0.9 - 5.5</td>
</tr>
<tr>
<td>LH mL/ml</td>
<td>4.0 - 8.0</td>
</tr>
</tbody>
</table>


Test Result Units Ref Range

Subject Five

SID: 207-2002 Serum Sample: 14/10/1993 Time 09:15 HR.

Act 19 1993 9:41 am Single Report